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Abstract 8 
 
Abstract 
 
Proteases play important roles in many physiological processes including the development 
and differentiation of the nervous system. To obtain an inventory of the trypsin-like serine 
proteases expressed in the spinal cord during the period of the maturation of the neuro-
muscular junction, a protease-enriched cDNA library was constructed. The library was 
generated from postnatal day 10 mouse spinal cord mRNA and allowed the retrieval of 27 
different trypsin-like serine protease sequence fragments. One sequence was not yet 
described to be part of any known protease. Using this fragment and the technique of rapid 
amplification of cDNA ends, the full-length sequence of a novel protease, designated 
neurobin, was obtained. Neurobin consists of 431 amino acids. Primary sequence analysis 
suggested that neurobin is a type II transmembrane serine protease (TTSP). Neurobin has a 
short N-terminal segment in the cytosol followed by a transmembrane-helix. In the 
extracellular part, neurobin contains a single SEA domain and the C-terminal serine 
protease domain. With this domain structure, neurobin belongs to the HAT/DESC 
subfamily of TTSPs. RT-PCR analysis indicated expression of neurobin in spinal cord and 
cerebellum. Histochemical analysis of brain sections revealed most distinct staining of 
Purkinje neurons of the cerebellum. Overexpression of neurobin in the cell-lines COS-7 
and HEK293T showed, that neurobin is autocatalytically processed and inserted into the 
plasma membrane. Autocatalytic activation could be suppressed by mutating Ser381 in the 
catalytic pocket to Ala. The protease domain of neurobin was produced in E. coli and 
purified from inclusion bodies. After activation, the refolded protease domain cleaved 
chromogenic peptides with Arg in position P1. Serine protease inhibitors effectively 
suppressed the proteolytic activity of recombinant neurobin. Aspartate and cyteine protease 
inhibitors, as well as EDTA or heparin had no influence on neurobin-activity towards 
chromogenic peptides. Ca2+ or Na+ ions did not significantly modulate the catalytic activity 
of the protease. In in vitro assays, fibroblast growth factor-2 was processed by recombinant 
neurobin at several P1 Lys and Arg positions to distinct fragments. This fragmentation 
could be inhibited by heparin in dose-dependent manner. Other proteins like fibroblast 
growth factor-7, laminin, or fibronectin were not processed in these in vitro assays. Taken 
together, these results indicate that neurobin is an authentic TTSP with trypsin-like activity, 
possibly high protein-substrate selectivity and restricted tissue distribution.  
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Zusammenfassung 
 
 
Proteasen spielen eine wichtige Rolle in vielen physiologischen Abläufen, einschliesslich 
der Entwicklung und Differenzierung des Nervensystems. Um ein Inventar der 
trypsinähnlichen Serinproteasen zu erhalten, die während der Reifungsphase der 
neuromuskulären Endplatte im Rückenmark exprimiert werden, wurde eine 
Proteasedomänen-angereicherte cDNA-Bibliothek erstellt. Bei der Herstellung der 
Bibliothek wurde mRNA aus dem Rückenmark von zehntägigen Mäusen verwendet. In 
der Bibliothek wurden cDNA-Klone gefunden, die Sequenzabschnitte von 27 
verschiedenen Serinproteasen codieren. Einer der Sequenzabschnitte liess sich keiner 
bekannten Protease zuordnen. Mit Hilfe einer Technik zur schnellen Vervielfältigung von 
cDNA-Enden wurde die vollständige cDNA Sequenz einer neuen Protease entdeckt, die 
den Namen Neurobin erhielt. Neurobin besteht aus 431 Aminosäuren. Die Analyse der 
Aminosäuresequenz ergab, dass Neurobin eine Typ II Transmembran-Serinprotease 
(TTSP) ist. Neurobin besteht aus einem kurzen zytosolischen Segment am N-Terminus, 
dem eine transmembranale Helix folgt. Im extrazellulären Teil des Moleküls befinden 
sich eine SEA- und dann die C-terminale Proteasedomäne. Wegen seiner 
Domänenkomposition gehört Neurobin in die HAT/DESC-Unterfamilie der TTSPs. RT-
PCR Experimente zeigten, dass Neurobin vor allem im Rückenmark und im Kleinhirn 
exprimiert wird. In histochemischen Färbungen wurde die deutlichste Neurobin-
Immunoreaktivität in Purkinje-Zellen gefunden. Bei der Überexpression von Neurobin in 
den Zelllinien COS-7 und HEK293T wurde Selbstaktivierung des Proteins und Insertion 
in die Zellmembran festgestellt. Diese Selbstaktivierung konnte durch die Mutation von 
Ser381 im katalytischen Zentrum zu Ala unterdrückt werden. Die Proteasedomäne wurde 
in E.coli hergestellt, aus Einschlusskörperchen aufgereinigt und rückgefaltet. Nach 
enzymatischer Aktivierung war die rückgefaltete Proteasedomäne in der Lage, 
chromogene Peptide nach Arg-Resten zu schneiden. Serinprotease-Inhibitoren hemmte 
diese proteolytische Aktivität. Aspartat- und Cysteinprotease-Inhibitoren sowie EDTA 
oder Heparin zeigten keinen Einfluss auf die Neurobin-Aktivität gegen chromogene 
Peptide. Der Einfluss von Calcium- und Natriumionen auf die katalytische Aktivität war 
gering. In in vitro Versuchen wurde der Wachstumsfaktor FGF-2 von Neurobin nach 
mehreren Lys- und Arg-Resten geschnitten. Diese Prozessierung konnte mit ansteigender 
Heparin-Konzentration vollständig unterdrückt werden. Andere Proteine, wie der 
Wachstumsfaktor FGF-7, Laminin oder Fibronektin wurden in keinem in vitro Versuch 
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prozessiert. Zusammengefasst zeigen die Resultate der Experimente, dass Neurobin eine 
TTSP mit trypsinähnlicher Aktivität und möglicherweise hoher Proteinsubstrat-
Selektivität ist und eine klar beschränkte Gewebeverteilung aufweist. 
 
 
 
 
Abbreviations 
 
aa   Amino acid(s) 
ATP   Adenosine triphosphate 
bp   Base pair(s)  
BSA   Bovine serum albumin 
Ca-P   Calcium-phosphate 
cDNA   Complementary deoxyribonucleic acid 
CIP   Calf intestinal alkaline phosphatase 
CMV   Cytomegalovirus 
(C)NS   (central) nervous system 
COS-7   Monkey African green kidney, SV40 transformed 
CS   Cover slip(s) 
CTP   Cytidine triphosphate 
d   Deoxy 
dd   Dideoxy 
DESC                       Differentially expressed in squamous cell carcinoma 
DIG   Digoxigenin 
DMEM  Dulbecco’s modified Eagle’s medium 
DNA   Deoxyribonucleic acid  
(E)GFP  (enhanced) green fluorescent protein 
ER   Endoplasmic reticulum 
FCS   Fetal calf serum 
FGF-2   Fibroblast growth factor 2 
Abbreviations 11 
GTP   Guanosine triphosphate 
H/MAT  Human/mouse airway trypsin-like  
HEK   Human embryonic kidney  
IF   Immunofluorescence  
kDa   Kilodaltons 
LTD   Long-term depression 
LTP   Long-term potentiation 
(m)NT   (murine) Neurotrypsin (full-length) 
(m)RNA  (messenger) Ribonucleic acid 
NS   Nervous system 
nt   Nucleotide(s) 
OD   Optical density 
ORF   Open reading frame 
PA   Plasminogen activator 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PFA   Paraformaldehyde  
PLL   Poly-L-lysine 
POD   Peroxidase 
PRB   Proline-rich basic 
RACE   Rapid amplification of cDNA ends 
RCF   Relative centrifugal field 
rpm   rotations per minute 
RT-PCR  Reverse transcription - polymerase chain reaction 
SDS-PAGE  Sodium dodecylsulfate-polyacrylamide gelelectrophoresis 
SEA   Sea-urchin/enteropeptidase/agrin 
SV40   Simian virus 40 
TBS   Tris buffered saline 
TMPRSS  Transmembrane serine protease 
tPA   Tissue-type plasminogen activator 
Tris   Tris-(hydroxymethyl)-methane 
TTP   Thymidine triphosphate 
TTSP   Type II transmembrane serine protease 
uPA   Urokinase-type plasminogen activator (urokinase) 
UTR   Untranslated region 
WB   Western blotting 
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1 Introduction 
 
1.1 Proteases 
 
Enzymes are proteins that serve as bio-catalysts. Thus, they enable living organisms to 
conduct most of the chemical reactions of their requirements in a narrow temperature- 
and pH-range in aqueous solution. Proteases, also known as peptidases, proteinases or 
proteolytic enzymes, catalyze the hydrolysis of peptide bonds. The analysis of deciphered 
genomes from a large variety of organisms revealed that about 2 % of all genes encode 
proteases making them the largest group of enzymes (Rawlings et al., 2006).  
 
Proteases cleave amid bonds between amino acids. By catalyzing this hydrolysis step, 
proteases are involved in a wide variety of biological functions ranging from unspecific 
protein degradation like in food digestion to sophisticated cascades like in blood 
coagulation where cleavage modulates the activity and function of proteins ((Mann, 
2003); and references therein). Similarly, proteases exert their function in wound healing, 
angiogenesis, clot dissolution, tissue development, antigen presentation, complement 
activation, memory formation/learning and apoptosis ((Puente et al., 2003a); and 
references therein). Thus, alterations in protease activity and/or expression pattern result 
in a large variety of pathological conditions. This makes activity modulation of certain 
members of this enzyme group a recognized concept for the treatment of conditions as 
different as thrombosis, Alzheimer and cancer. 
 
Proteases are often subdivided according to their catalytic types. Five types are classified 
depending on the amino acid in their catalytic center being aspartate, cysteine, glutamate, 
serine or threonine. Additionally, there is one type in which metal ions such as Zn2+ or 
Cu2+ form the catalytic center. A seventh division of proteases summarizes those 
enzymes, of which the catalytic type is unknown till date (MEROPS, the peptidase 
database, Release 7.90, http://merops.sanger.ac.uk). Besides, proteases are divided into (a) 
exopeptidases, which cleave either amino acids from the N-terminus (aminopeptidases) 
or from the C-terminus (carboxypeptidases) of a peptide chain, and (b) endopeptidases, 
which cut within a peptide chain. The largest family of endopeptidases consists of serine 
proteases of the chymotrypsin-type, the peptidase family S1 or chymotrypsin family 
(Rawlings et al., 2007).  
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Another useful classification into clans is based on structural fold similarities which 
suggest common evolutionary origins (Rawlings and Barrett, 1999). Family S1 members 
belong to the clan PA and, being serine proteases, to subclan PA(S). This introduction 
will focus mainly on proteases of family S1 and repeatedly refer to subfamily S1(A) 
which contains three quarters of all family S1 members (MEROPS, the peptidase 
database, Release 7.90, http://merops.sanger.ac.uk). 
 
1.2 Peptidase subfamily S1(A) 
 
The serine proteases of subfamily S1(A) can be further subdivided according to the 
substrate amino acids preceding the cleaved peptide bond into (I) chymotrypsin-like 
(hydrolysis after hydrophobic amino acids), (II) elastase (after alanine), (III) granzyme B 
(after acidic amino acids) and (IV) trypsin-like (after the basic amino acids arginine and 
lysine) enzymes ((Hedstrom, 2002); and references therein). Numbering of the amino 
acids of the catalytic domain is often adjusted to the chymotrypsin numbering proposed 
by W. Bode (Bode et al., 1989) to facilitate comparisons and generalizations while 
analyzing different family S1(A) members. Using chymotrypsin numbering, e.g. the most 
conserved amino acids of subfamily S1(A) members will always be found in sequence 
position 57, 102 and 195, respectively. Chymotrypsin numbering will be used throughout 
the whole introduction section when referring to catalytic domains.  
 
In subfamily S1(A) proteases, the catalytic domain is often preceded by one to several 
non-catalytic domains of various types that mediate substrate- and other protein-
interactions ((Bowen et al., 2000; Chang et al., 1997; Stahl et al., 1996; Xue et al., 2001); 
and others). An obvious difference between subfamily A and B is that in subfamily B 
non-catalytic domains occur also C-terminally of the protease domain. Interestingly, 
while most non-catalytic domains are modules also found in other proteins, the apple and 
kringle domains almost exclusively occur in proteases of family S1 (MEROPS, the 
peptidase database, Release 7.90, http://merops.sanger.ac.uk). 
 
Subfamily S1(A) proteases are secreted or membrane-bound proteins with the catalytic 
domain facing the extracytosolic lumen. 
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1.3 The catalytic mechanism of peptide hydrolysis by family 
S1 proteases 
 
The structure of the catalytic domains of family S1 proteases is molded by two six-
stranded beta barrels. The fold allows the primary substrate recognition region and the 
catalytic center to arrange in the cleft between the barrels (Figure  1.1).  
 
Figure  1.1: To represent the fold of subfamily S1(A) peptidases a ribbon model of trypsin is shown 
with the two six-stranded beta barrels (blue) at right angle to one another. Backbone and side chain 
atoms of the catalytic triad and Asp189 at the bottom of the primary specificity pocket are depicted 
in black sticks, six cysteine residues forming three highly conserved disulfide bridges are shown in 
yellow and the termini are labeled. The model was generated using the x-ray structure 1YP9 in the 
Swiss PDB Viewer (Guex and Peitsch, 1997). 
 
The catalytic center is composed of the catalytic triad consisting of His57, Asp102 and 
Ser195 and the oxianion hole, formed by the backbone NH-groups of Gly193 and Ser195. 
The catalytic triad is part of a long ranging hydrogen bonding network. This hydrogen 
bonding system allows the activation of Ser195 for the nucleophilic attack on the 
carbonyl group of the scissile peptide bond (the bond which is hydrolyzed). The 
positively charged oxianion hole in turn prepares the attacked carbonyl group by 
increasing its electrophilicity and it stabilizes the resulting oxyanion of the first 
tetrahedral intermediate. The intermediate collapses expulsing the C-terminal peptide of 
the cleaved substrate carrying the proton originating from Ser195. The resulting 
acylenzyme intermediate is nucleophilically attacked by water activated by the hydrogen 
bonding network around His57. After collapse of the resulting second tetrahedral 
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intermediate, the second peptide is released and the enzyme is obtained in the original 
state after propagation of the proton captured by His57 to Ser195 (Figure  1.2).   
The catalytic mechanism was nicely reviewed in more detail by L. Hedstrom (Hedstrom, 
2002) but is also comprehensively explained in textbooks like “Biochemistry” by D. Voet 
& J.Voet. 
 
Figure  1.2: The generally accepted catalytic mechanism of serine proteases is shown. The oxyanion 
hole (OA) prepares the substrate’s carbonyl group for the nucleophilic attack by Ser195, which leads 
to the first tetrahedral intermediate (1). Upon collapse, the acyl-enzyme intermediate is obtained, 
which is attacked by water while the N-terminal cleavage product is released (2). This leads to the 
second tetrahedral intermediate (3). Upon collapse, the active enzyme is retained as soon as the C-
terminal substrate peptide diffuses away (4). Figure was modified from Voet&Voet, 1996. 
 
Interestingly, a catalytic mechanism similar to that applied by S1 proteases appears to 
have evolved independently in subtilisin (clan SB) in which another sequence order of the 
catalytic triad (Asp-His-Ser) and a different form of oxianion hole (side chains of two 
amino acids plus one backbone NH-group) was found (Matthews et al., 1975). Moreover, 
the catalytic triad is found in proteases of the clans SC (Ser-Asp-His) and SK (Ser-His-
Asp) but also in e.g. lipases (Asp-His-Ser) (Dodson and Wlodawer, 1998). These various 
manifestations of the catalytic triad are considered as examples for convergent molecular 
evolution to obtain an efficient charge relay system. However, the charge relay system 
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generating the nucleophilic potential of the Ser195 side chain oxygen in S1 family 
members can also be obtained by a different composition of the triad as observed for 
proteases of the clan SH in which the Asp is substituted by His (His-Ser-His; Figure  1.3). 
In this chase the rest of the catalytic machinery is conserved, suggesting another variant 
of convergent evolution (Chen et al., 1996). 
 
 
Figure  1.3: Superposition of the catalytic triads of clan PA(S) (trypsin), clan SB (subtilisin) and clan 
SH (human cytomegalovirus assemblin) reveals striking similarities of the overall architecture of the 
catalytic center. Picture taken from (Dodson and Wlodawer, 1998).   
 
1.4 Control of catalytic activity and introduction to 
additional characteristics of family S1 proteases 
 
Cells and organisms make use of a variety of techniques to prevent destructive effects of 
proteolytic activity: Often proteases are produced in a catalytically inactive proform, the 
zymogen. Further, proteases activity is modulated by inhibitors and degradation of the 
protease (Bode and Huber, 2000). Controlled secretion, high specificity for substrate 
cleavage motifs, strict spatio-temporal expression patterns of proteases, and allosteric 
regulation and exosite interactions are further ways to minimize unwanted harmful effects 
of proteolysis. 
Activation in family S1 proteases occurs by proteolytic cleavage of the zymogen after an 
Arg or Lys residue in position 15. Upon cleavage, the newly generated protonated N-
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terminus forms a salt bridge with the side chain carboylate group of Asp194. The 
resulting structural rearrangements open the substrate binding cleft and adjust the 
residues of the oxianion hole (Khan and James, 1998). This activation mechanism is 
conserved in mammalian S1 family members and generally leads to an enzyme that is six 
to seven orders of magnitude more active than the zymogen. A famous exception is the 
zymogen of tissue-type plasminogen activator (tPA) which is only one order of 
magnitude less active than the activated enzyme. In this special case, the Lys156 side 
chain forms an ion pair with the side chain carboylate group of Asp194 which has a 
similar effect as the salt bridge formed by this residue to the N-terminus generated upon 
activation cleavage (Renatus et al., 1997).  
 
Once activated, several S1 family members like trypsin and human kallikrein 6 are 
capable of self-activation by autocatalytic cleavage of zymogens (Magklara et al., 2003).  
 
In general, the noncatalytic part of family S1 proteases stays covalently linked to the 
protease domain after activation cleavage. This is possible due to a disulfide bridge 
formed by a cysteine residue preceding the activation cleavage site and a cysteine in 
position 122 on the surface of the protease domain. 
 
In living organisms, inhibition of serine proteases is frequently realized by proteins that 
bind in a substrate like manner, with a fixed distance to the catalytic center too far to 
induce catalysis. As an example the complex of the trypsin-like serine protease thrombin 
and rhodniin (an inhibitor that prevents blood coagulation in the prey of the assassin bug 
Rhodnius prolixus), in which the scissile peptide bond is fixed at a van der Waals 
distance of 2.7 Å from the Oγ atom of the Ser195 residue of thrombin, was reviewed 
recently (Bode and Huber, 2000).  
 
Other important physiological inhibitors are from the serpin family (serine protease 
inhibitor, MEROPS family I4). For inhibition, serpins become first cleaved in their 
reactive-center loop like normal substrates. However, immediately upon cleavage the 
reactive-center loop, ester-linked to Ser195, flips over and becomes inserted into a beta 
sheet of the serpin structure. The process is very fast and the energy gained from the loop 
insertion is large enough to tear Ser195 away from its catalytic partners and deform the 
oxianion hole (Huntington et al., 2000). Thus, formation of the second tetrahedral 
intermediate is prevented and the enzyme is blocked (Figure  1.4). 
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Figure  1.4: Ribbon depictions to visualize the inactivation mechanism of serpins on serine proteases. 
Left: Trypsin (cyan, with helices in magenta for orientation) attacks the reactive-center loop (yellow,; 
green ball-and-stick, P1 Met) of the serpin 1-antitrypsin (gray, with its -sheet A colored in red). 
Upon cleavage, the cleaved reactive-centre loop is fully inserted into the A-sheet (right). This rapidly 
flips the complexed trypsin to the other side of the serpin molecule leading to disordered regions in 
the protease domain. Picture modified from (Huntington et al., 2000). 
 
Specificity of family S1 proteases is strongly influenced by the polypeptide binding site 
and the substrate (side chain) binding pockets. The enzyme’s polypeptide binding site is 
generated by the main chain atoms of residues 214-216 forming an antiparallel beta sheet 
with the backbone of the substrate residues preceding the scissile peptide bond. The 
extended conformation of the substrate in the antiparallel beta sheet is referred to as the 
“canonical conformation”. Because of the canonical conformation, the substrate’s side 
chains point in alternating directions (Hedstrom, 2002). In the nomenclature proposed by 
Schechter and Berger (Schechter and Berger, 1967), P1 denotes the peptide residue on the 
acylgroup side of the scissile bond and the adjacent residues are numbered outward P2-Pn, 
respectively. The corresponding substrate binding pockets on the enzyme are termed S1-
Sn, respectively. Similarly, the residues on the substrate’s leaving group side are termed 
P1’-Pn’ and their binding pockets on the enzyme S1’-Sn’, respectively. 
  
As mentioned in paragraph 1.2, the preferred amino acids binding to the S1 pocket allows 
further subdivision of subfamily S1(A) proteases. Specificity of the S1 binding pocket 
lying adjacent to Ser195 is mainly determined by the residues at positions 189, 216 and 
226 (Czapinska and Otlewski, 1999). Interestingly, exchanging the S1 binding pocket 
residues does not efficiently convert the specificity of one subfamily member to that of 
another one. Thus, to obtain for example a significant chymotrypsin-like activity of the 
trypsin framework additional mutations in surface loops are required (Hedstrom et al., 
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1994). However, since crystal structure analysis revealed that mutations in the S1 pocket 
had unanticipated effects on the arrangement of the catalytic center, it is likely that the 
additional loop mutations were necessary to simply counterbalance these effects (Szabo 
et al., 2003a).  
Substrate specificity as a real measure of protection from unwanted proteolysis is of 
cause only realized when additional binding pockets display clear side chain selectivity as 
observed for enteropeptidase in which ideally four aspartate residues bind to pockets S2-
S5 (Lu et al., 1999). Another possibility to generate protection via specificity is realized 
in induced fit proteases like complement factor D, which only upon binding of its natural 
substrate, the complement complex C3bB, recovers from the self-inhibited state (Jing et 
al., 1999). 
Restrictions in the expression pattern as a measure of protection might be realized by 
matriptase-2 and hepsin, both mainly expressed in liver and kidney in adult mice and with 
varying peaks also in other organs during embryonic development (Hooper et al., 2003). 
 
Often nature makes use of a combination of the activity control mechanisms mentioned 
above. Virtually all mechanisms are involved in the activity control of the digestive 
enzyme trypsin. Trypsin is produced by the pancreas - as a zymogen as a first safety 
measure to prevent digestion of this organ. Trypsinogen, accidentally activated in this 
organ is inhibited by kunitz-type inhibitors like bovine pancreatic trypsin inhibitor. A 
further safety measure is the storage in zymogen granules thought to be resistant to 
enzymatic degradation. Besides, the four aspartate residues preceding the Lys15 in the 
zymogen activation region are thought to reduce self-activation or activation by other 
proteases produced by the pancreas (Voet&Voet, 1995). Upon secretion into the 
duodenum trypsinogen is activated by enteropeptidase. Enteropeptidase with its very 
restricted expression in the duodenum activates by cleaving trypsinogen’s DDDK15 
motif with high specificity. Trypsin activates further zymogens ranging from in turn 
enteropeptidase and trypsin, to chymotrypsins, elastase, kallikreins and carboxipeptidases 
that in concert digest peptides from food uptake. After nutrition-substrate depletion, 
trypsin and the other proteases inactivate themselves by self-cleavage (Szmola and Sahin-
Toth, 2007) - the final control and recycling step.  
 
1.4.1 Possible ways of initial enteropeptidase activation 
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There is a theoretical “egg-hen” problem in the trypsin activation model. How does the 
first trypsinogen become activated if mainly trypsin activates its activator enteropeptidase 
(Lu et al., 1997). Actived enteropeptidase might reside in the sober duodenum starting 
very early in development without causing harm due to the high cleavage motif 
specificity, its low concentration and also because of being membrane-bound to the 
mucous-coated duodenum wall. However, initial enteropetidase activation might well 
occur via trypsin since once in the duodenum trypsinogen is not longer strictly controlled 
by high inhibitor concentration. Single trypsin molecules, capable of starting a snowball-
like amplification of active proteases, will be generated by one way or the other. 
Interestingly, not only proteases surviving their gastric journey are candidate initial 
activators of trypsin or enteropeptidase. Even peptides might do the job since it was 
shown that the free dipeptide Ile-Val, by binding in the Ile16-cleft, can form a salt bridge 
to Asp194 that leads to catalytically active trypsinogen form (Khan and James, 1998). 
Besides, duodenase was proposed to be the initial activator of enteropeptidase 
(Zamolodchikova et al., 2000). However, if this was true, is would only shift the problem 
to another zymogen. Nonetheless, “shifting” up the activation cascade might be adequate; 
eventually proteases with a zymogen activity similar to that of tPA might be encountered. 
Alternatively somewhere up the activation cascade another type protease might be found, 
that is not activated as a zymogen. 
A surprising observation was that for human enteropeptidase the DDDK15 motif is not 
needed for trypsin activation (Nemoda and Sahin-Toth, 2005). It was argued that exosite 
interactions ensure efficient trypsin activation in this case. At least partially, these exosite 
interactions reside on the one or several of the seven noncatalytic domains of 
enteropeptidase (Lu et al., 1997). Exosite interactions, as further elements of substrate 
specificity are extensively used by coagulation proteases (Page et al., 2005). 
 
1.4.2 Allosteric Regulation and Exosite Interactions in Thrombin 
 
Thrombin is famous for its dual role in blood coagulation (Griffin, 1995). The varying 
activities of thrombin are strongly dependent on exosite interactions, interactions of 
substrate molecules with the protease via regions other than the catalytic cleft. In 
thrombin exosite interactions are thought to reside mainly if not completely on the 
protease domain. There are two exosite interaction regions found in thrombin that are 
conserved in family S1 proteases. Exosite I overlaps with a potentially calcium binding 
loop (Page et al., 2005), a site of allosteric regulation (see below). On the opposing side 
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of the catalytic cleft locates exosite II. Exosite II bears a high number of positively 
charged residues and is the main interaction site for polyanionic ligands like 
glucosaminoglycans and heparin (Carter et al., 2005). 
Varying exosite interactions of the thrombin protease domain with different substrates are 
crucial for the procoagulant and anticoagulant functions. Na+-binding allosterically 
regulates specificity and promotes these opposing effects of thrombin (Di Cera, 2007). In 
general, family S1 proteases are known to be allosterically regulated by Na+ if tyrosine is 
present in position 225 (like in thrombin) and sodium-insensitive if this position is 
occupied by proline (Dang and Di Cera, 1996). Binding of the sodium ion orients Asp189 
in the S1 pocket and, via a network of buried water molecules, positions Ser195 for 
catalysis (Pineda et al., 2004). Additional allosteric effects in several family S1 proteases 
are mediated by Ca2+ complexation via acidic side chains of peptide residues in the 70-80 
loop. However, thrombin is Ca2+-insensitive because its Lys70 side chain occupies the 
position of the calcium ion.   
In the concrete case of thrombin, Na+-binding determines whether several interactions of 
the protease domain lead to blood clot formation or to the activation of protein C . 
 
Figure  1.5: Schematic representation of the sodium-dependent multiple roles of thrombin. Under 
physiological conditions 60 % of all thrombin molecules in the blood are in the sodium-bound form. 
This allows efficient activation of factors V, VIII and XI leading to coagulation. This thrombin form 
also efficiently induces signaling by cleaving protease activated receptors (PARs) 1, 3, and 4. All effects 
that abolish sodium-ion complexation favor association of thrombin with its cofactor thrombomodulin 
(TM)  leading to protein C (PC) activation and the resulting anticoagulating effects. Modified from (Di 
Cera, 2007). 
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Under physiological sodium concentrations 60 % of thrombin is in the sodium-bound 
form (Di Cera, 2007) which allows fibrinogen cleavage (leading to fibrin polymers), 
transglutaminase activation (crosslinks the polymers thereby stabilizing the fibrin clot) 
and activation of molecules upstream of its own zymogen (factors V, VIII and XI), 
further accelerating and strengthening the coagulation cascade (Voet and Voet, 1995). 
Besides, the sodium-bound form of thrombin efficiently activates protein coupled 
receptors (PAR1, PAR3 and PAR4) by cleavage, leading to cell signaling and, in the case 
of blood coagulation, to platelet activation and aggregation (Coughlin, 2000). The other 
40 % of thrombin are sodium-free and incapable of promoting physiologically relevant 
fibrin or PAR1 activation (Page et al., 2005). However, upon binding to the cofactor 
thrombomodulin this thrombin form efficiently activates protein C, which cleaves and 
inactivates factors V and VIII leading to a shut down of the coagulation cascade (Esmon, 
2003). Interestingly, by mutating only two surface residue, the protein C activating effect 
of thrombin becomes so dominant that the coagulation protease thrombin gains interest as 
antithrombotic agent (Gruber et al., 2007).   
 
1.5 The Extracellular Matrix (ECM) 
 
Extracellular matrix proteins are a prerequisite for the existence of multi-cellular 
organisms (Patthy, 2003). In cartilage and bone the ECM is dominant for the function of 
these tissues, whereas in many organs the ECM functions as glue between cells. A lot of 
signaling in this glue ensures proper functioning and adaptations to changing needs of the 
organism. The ECM has three main components. The (I) collagens, differentially 
combined from a large variety of alpha subunits, render stability and flexibility to the 
ECM. The (II) linking proteins like fibronectin and laminin mediate interactions between 
the various parts of the ECM and build the connections between ECM and cells via the 
integrin family of cell surface receptors. The (III) proteoglycans fill most of the space in 
the ECM by generating a hydrated gel via their attached glycosaminoglycans (GAGs). 
GAGs consist of large unbranched polymers composed of 20-200 repeating disaccharide 
units. Depending on the disaccharide units one differentiates between 
chondroitin/dermatan sulfate, heparin/heparan sulfate, and keratan sulfate and hyaluronan 
GAGs (Bandtlow and Zimmermann, 2000; Kjellen and Lindahl, 1991). Proteoglycans 
bind many growth factors, proteases, and protease inhibitors, mainly via their GAGs. In 
part this provides the basis for the signaling function of the ECM (Flaumenhaft and 
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Rifkin, 1991). In addition, proteoglycans have signaling function by themselves. As 
observed for example in agrin (Bezakova and Ruegg, 2003) in which the physiological 
effects are at least partially dependent on proteolytic processing by the S1 family protease 
neurotrypsin (Reif et al., 2007). The same is true for the other components of the ECM. 
For example in fibronectin, cleaved by the S1 family protease human kallikrein 8 or in 
type IV collagen, cleaved by the matrix metallo protease 9, proteolytic processing is 
necessary to liberate the signaling function of certain protein fragments (Hamano et al., 
2003; Sher et al., 2006). The fragments are thought to possess antiangiogenic properties 
mediating favorable outcomes in cancer. This is evidence for the emerging roles of 
proteases in tumor suppression (Lopez-Otin and Matrisian, 2007) in addition to the long 
known effects of proteases in tumor progression by e.g. increased tumor cell motility 
upon matrix degradation.  
 
1.6 FGF-2 
 
FGF-2, also known as basic fibroblast growth factor, is a heparin binding molecule 
(Gleizes et al., 1995). This prototypic member of a family of 22 proteins is an ubiquitous 
growth factor conserved throughout the eukaryotic world (Yu et al., 2007a). FGF-2 
signaling contributes to proliferation, angiogenesis, cell survival, migration and 
differentiation (Mason, 1994).  
FGF-2 is peculiar in many ways. For example, it can be found in the cytosol, the nucleus 
and in the extracellular space. While most extracellular proteins in eukaryotes are 
secreted via the endoplasmic reticulum (ER)/Golgi dependent main export route (Lee et 
al., 2004), FGF-2 belongs to the small group of unconventionally secreted molecules 
(Cleves, 1997; Nickel, 2005). Consistently, FGF-2 lacks post-translational modifications 
of the type added in the ER/Golgi complex and, for example, does not contain disulfide 
bridges involving any of its four cycteines (Arakawa et al., 1989). 
Recently, it was shown that heparan sulfate proteoglycans are essential for the 
unconventional FGF-2 secretion - probably ensuring directionality of the transport by 
serving as molecular traps (Zehe et al., 2006). Upon secretion, FGF-2 is stored bound to 
proteoglycans and mediates short-range signaling in the ECM but also mediates long 
range signaling by traveling attached to proteolytically processed proteoglycans (Hou et 
al., 2007). Interestingly, FGF-2 signaling is not always depend on FGF-receptor mediated 
phosphorylation cascades. To induce proliferation, FGF-2 is translocated to the nucleus 
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upon import from endosomes. This import was recently shown to require the cytosolic 
chaperon Hsp90 (Wesche et al., 2006). Another noteworthiness of FGF-2 is the existence 
of high molecular weight (HMW) isoforms (four in human with molecular masses of 22, 
22.5, 24 and 34 kDa, respectively) that are generated upon translation from 
unconventional CUG start codons (Arnaud et al., 1999). Translation of only the low 
molecular weight (LMW) form of FGF-2 (most often referred to as “18 kDa form”, 
although the full-length protein containing 155 amino acids has a molecular mass of 17.2 
kDa) starts from a conventional AUG codon (Figure  1.6). 
 
 
Figure  1.6: Schematic representation of FGF-2 isoforms resulting from alternative translation. In the 
upper part, the human FGF-2 mRNA is shown in green with the relative positions of translation 
starts and stop indicated. Below, the low-molecular weight (LMW) form and the four different high-
molecular weight (HMW) isoforms of FGF-2 are shown with nuclear localization signals depicted in 
red. Figure adapted from (Okada-Ban et al., 2000).  
 
Post-translational methylation of arginines in the RG-rich N-termini of HMW FGF-2 
isoforms leads to nuclear accumulation (Klein et al., 2000). Oxidative stress induces 
increased secretion of all variants (Yu et al., 2007b). Such effects likely influence the 
various biological roles of FGF-2. More complexity in the mode of action is introduced 
by FGF-2 proteolysis. Thrombin converts the HMW forms of FGF-2 to a LMW-like form. 
These cleavages convert cell transforming and cell migration arrest effects of HMW 
FGF-2 to the proliferative and pro-migratory effects of the short form (Yu et al., 2007b). 
 
1.7 Introduction of Selected Family S1 Proteases in the 
Nervous System 
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Also in the central nervous system (CNS) proteases of family S1 play important roles.  
Like in other organs, they exert their function by inducing signaling via cleavage of PARs, 
release of signaling molecules or the processing of growth factors. And like in blood 
coagulation family S1 members in the CNS participate in peptidase cascades or degrade 
ECM components like in other tissues. In the CNS, however, some of the proteolytic 
processes lead to effects exclusively associated with the function of this organ. These 
effects include axonal outgrowth, synapse elimination (Figure  1.7) and structural 
plasticity associated with learning and memory ((Molinari et al., 2003); and references 
therein). 
 
Figure  1.7: Impressive in vivo fluorescence microscopy follow-up pictures illustrating the process 
called synapse elimination: At post natal day 8 (P8), two axons, two axons (labeled with different 
fluorescent proteins) innervate the same neuromuscular endplate. In the following days the axons 
compete for the control of the entire muscle nerve interaction interface. On P15, the blue axon won 
the battle while the green labeled axon retracted completely. Scale bars equal 10 µm, pictures taken 
from (Walsh and Lichtman, 2003). 
 
The family S1 proteases with a specialized function in the CNS are often known already 
to play important roles in other processes. Thrombin for example, encountered already in 
the blood coagulation, potentiates the NMDA (N-methyl-D-aspartate) receptor activity in 
the hippocampus via PAR-activation. This leads to long-term potentiation (LTP) of 
synaptic strength (Gingrich et al., 2000). LTP and long-tern depression (LTD), the 
reduction of electric efficacy of synapses are associated with the only morphological 
changes observed in processes of memory formation and learning (Kandel, 2001). PARs 
are widely expressed in the brain (Striggow et al., 2001). However, it is likely that 
thrombin might not promote all of its effects on neuronal survival and migration by 
activating these receptors but as well by using other signaling pathways e.g. involving 
FGF-2 processing (Yu et al., 2007b). 
Another example of a famous protease with a specialized function in the brain is tissue-
type plasminogen activator (tPA). In the blood, tPA activates plasmin resulting in fibrin 
degradation and clot dissolution. In the brain increased levels of tPA were detected upon 
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motor learning sessions and LTP induction (Qian et al., 1993). Mice in which the tPA 
gene was knocked out showed impaired motor learning (Seeds et al., 2003). Probably, in 
this process tPA cleaves plasminogen like in the blood. In the CNS, plasmin cleaves the 
proform of brain-derived neurotrophic factor (proBDNF) and it was shown that 
tPA/plasmin-dependent release of BDNF is essential for LTP in the hippocampus (Pang 
et al., 2004). 
On the other hand, there are family S1 proteases that appear to exert their function 
predominantly in the CNS. For example mouse neuropsin (human tissue kallikrein 8, 
mentioned already for its reducing effect on tumor cell invasiveness (Sher et al., 2006)) is 
predominantly expressed in pyramidal neurons of the hippocampus and influences 
synapse formation by cleaving the presynaptic adhesion molecule L1 (Matsumoto-Miyai 
et al., 2003). Another example is neurotrypsin. mRNA expression of neurotrypsin is 
upregulated in many brain regions of mice in the developmental stage around birth 
(Wolfer et al., 2001). As mentioned, neurotrypsin cleaves agrin (Reif et al., 2007), 
thereby exerting a crucial role during the establishment of the neuromuscular junction 
(Bolliger, in prep.) in mice. The absence of neurotrypsin activity in the brain leads to 
severe mental retardation in humans (Molinari et al., 2002).  
 
1.8 Type II Transmembrane Serine Proteases 
 
More than 20 % of all human proteases are membrane-bound, which emphasizes the 
relevance of proteolytic activity at this cellular interface (Puente et al., 2003a). Recently 
performed extensive database analyses and experimental screens revealed the existence 
of a novel family S1 protease subgroup named type II transmembrane serine proteases 
(TTSPs) ((Hooper et al., 2001; Netzel-Arnett et al., 2003; Szabo et al., 2003b; Wu, 2003); 
and others) with more than 30 mammalian members to date (Kyrieleis et al., 2007). 
Enzymes of this subgroup are composed of a usually short cytosolic N-terminus, a single 
transmembrane helix, a stem region containing a variable set of six different noncatalytic 
domains (low-density lipoprotein receptor class A (LDLA), SEA, Frizzled, MAM, CUB, 
and Group A scavenger receptor domain), and the C-terminal trypsin-like protease 
domain. TTSPs are divided into four subfamilies (Figure  1.8) based on the phylogenetic 
analysis of their protease domain, the composition of their stem region, and the 
chromosomal location of their genes (Szabo et al., 2003b). Their genes, as is the case for 
other proteases, are often organized in clusters, suggesting evolution via gene duplication 
(Puente et al., 2003a). The N-terminal segments of TTSPs might interact with cytosolic 
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components like the cytoskeleton and often contain phosphorylation sites. However, no 
study addressed the function of these segments till date. 
 
 
Figure  1.8: Schematic representations of the fifteen best-known human TTSPs grouped into the four 
subfamilies. Taken from (Szabo et al., 2003b).  
 
The non-catalytic domains in the stem region might be important for substrate interaction 
as already mentioned for the human form of the TTSP enteropeptidase (Lu et al., 1997). 
Additionally, these domains are involved in targeting the molecule to secondary 
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interaction partners on the cell surface or in the ECM and contribute to the orientation of 
the catalytic domain (Kyrieleis et al., 2007). The non-catalytic domains of TTSPs also 
contribute to the activation of the enzyme. Interestingly, in such processes even non- 
enzymatic hydrolysis of peptide bonds might play a role. For example in the sophisticated 
activation process of matriptase, which involves transient interactions with its cognate 
inhibitor HAI-1 via LDLA domains(List et al., 2006), hydrolysis after Gly149 in the 
conserved G-SVIA motif in the SEA domain always occurs during activation under 
physiological conditions (Oberst et al., 2003). Recently, SEA domain autohydrolysis was 
discussed as a general way to enable dissociation as a result of mechanical rather than 
chemical stress on apical cell membranes (Macao et al., 2006). 
Physiological functions of TTSPs were increasingly uncovered in recent years. The 
identification of mutations in the gene coding for TMPRSS3, in patients with congenital 
autosomal recessive deafness, suggested a role of this TTSP in hearing (Scott et al., 
2001). Ablation of the matriptase gene in mice demonstrated a critical role of this TTSP 
in the development of the epidermis, hair follicles, and cellular immunity (List et al., 
2002). Transgenic overexpression of matriptase caused spontaneous squamous cell 
carcinoma and potentiated carcinogen-induced tumor formation (List et al., 2005). Mice 
with a null mutation in the gene encoding the TTSP corin developed hypertension (Chan et 
al., 2005). Deletion of the hepsin gene in mice demonstrated a significant role of this 
protease in auditory function (Guipponi et al., 2007). Experimental overexpression of 
hepsin promoted prostate cancer progression and metastasis (Klezovitch et al., 2004). Such 
findings underscore the involvement of TTSPs in a variety of vital functions. 
Molecular analysis of TTSP proteolytic activity allowed the identification of a broad 
spectrum of possible substrates. Matriptase-2 multiply cleaved type I collagen and 
fibronectin (Velasco et al., 2002). TMPRSS3 activated epithelial sodium channels 
(Guipponi et al., 2002). TMPRSS2 activated protease-activated receptor-2 in prostate 
cancer cells (Wilson et al., 2005), and hepsin cleaved and activated pro-hepatocyte growth 
factor and pro-urokinase (Kirchhofer et al., 2005; Moran et al., 2006). 
Many TTSPs show a restricted expression pattern, suggesting tissue-specific functions. 
Enteropeptidase, e.g., is confined to the proximal part of the small intestine and acts as an 
activator of trypsinogen (Yuan et al., 1998). Corin is mainly present in heart myocytes 
(Hooper et al., 2000) and mediated pro-atrial natriuretic peptide activation (Yan et al., 
2000). Interestingly however, corin was recently reported to be also expressed in the 
dermal papilla of all pelage hair follicle types (but nowhere else in skin) and to be 
responsible for the coat color development in agouti mice (Enshell-Seijffers et al., 2008). 
Introduction 29 
HAT (human airway trypsin-like) is predominantly expressed in the trachea (Yamaoka et 
al., 1998) and DESC1 (differentially expressed in squamus cell carcinoma) is expressed 
in skin, additionally in the salivary gland and epididymis (Hobson et al., 2004). Together 
these two TTSPs give name to the yet scarcely investigated HAT/DESC subfamily with 
five members in humans and seven members in mice (Hobson et al., 2004), located in 
clusters on chromosome 4q13.3 and 5E1, respectively (Figure  1.9). 
DESC1 was initially found being downregulated or absent in squamus cell carcinoma of 
the head and neck and thus, was suggested as a tumor marker (Lang and Schuller, 2001). 
Recently however, exogenous DESC1 expression was shown to confer tumorigenic 
properties to Madin-Darby canine kidney cells and DESC1 was found upregulated in 
tumors originating from tissues of different origin than the head and neck (Viloria et al., 
2007). DESC1 might have a physiological role in normal keratinocyte differentiation 
(Sedghizadeh et al., 2006). 
 
 
Figure  1.9: Schematic representation of the gene clusters of the HAT/DESC TTSP-subfamily in mice 
and man, with seven and 5 members, respectively. Taken from (Hobson et al., 2004). 
 
 
In the nervous system, only spinesin was so far identified as a TTSP expressed by 
neuronal cells (Yamaguchi et al., 2002). The function of spinesin is not known till date. 
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2 Aim of the project 
 
 
In view of the complex differentiation processes of the nervous system, it is evident to 
assume that many proteases of family S1, including known and possibly novel TTSPs, 
are involved. This assumption is supported by results of extensive mouse genome 
analyses that predict the existence of more than 220 serine protease genes or pseudogenes 
(Puente et al., 2003b). Therefore, the first aim of the project was to obtain an inventory of 
trypsin-like serine proteases expressed during CNS development and during such 
fascinating differentiation processes as synapse elimination. 
Therefore, we established a PCR-based screening approach using postnatal day 10 (P10) 
mouse spinal cord. We detected expression of at least 21 non-TTSP serine proteases and 
five known TTSPs. Additionally, we discovered a novel TTSP which became subject of 
our characterization attempts. 
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3 Results 
3.1 Generation of a protease domain enriched cDNA library 
and library screening by colony hybridization 
 
To estimate the number of serine proteases expressed in differentiating mouse spinal 
cord, we generated and screened a serine protease domain-enriched cDNA library. The 
library contained the 400 – 600 bp products of a PCR in which cDNA from P10 mouse 
spinal cord mRNA had been used as template with degenerated primers. The primers were 
designed to anneal to the regions of His57 and Ser195 (chymotrypsin numbering as proposed by 
(Bode et al., 1989)), the most conserved motifs in the catalytic triade of trypsin-like serine 
proteases. To design the primers we used the alignment of 177 sequences of known and 
postulated serine proteases (http://supfam.org/SUPERFAMILY/index.html, version 1.61). 
After the elimination of 48 false positive entries among the postulated proteases, e.g. hepatocyte 
growth factor like sequences, the most prevalent sequences in the alignment were WVLTAAH57C 
and GDS195GGP (Figure  3.1).  Four degenerated primers allowing codons of these and a few 
other amino acids and introducing a 5’ endonuclease restriction site (EcoRI) were ordered (Figure 
 3.2). 
 
 
Figure  3.1: Human Neurotrypsin with its noncatalytic N-terminal domains is depicted as a typical 
example of a trypsin-like serine protease. The sequence of the protease domain (PROT) is relatively 
well conserved amongst trypsin-like serine proteases. The order of its catalytic triad in the amino 
acid (aa) sequence is shown. Especially in the region around His57 and Ser195 the sequence is highly 
conserved (the most prevalent sequence is shown). Degenerated primers annealing in this region 
result in PCR products of the indicated length for most members of this protein family. 
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First, combinations of the four primers were tested on a mixture of 10 pg plasmid containing the 
mouse neurotrypsin sequence. The primer-combination +PrimerH long and –PrimerS short gave a 
very clear single PCR product band with our pretest conditions. For this degenerated primer pair, 
DMSO and Mg2+- ion concentrations as well as annealing temperature and cycle number were 
subsequently optimized in PCR with single-stranded cDNA as template. The PCR products of 
400 to 600 bp in length were purified and ligated into pBlueskriptSK+ vector via the EcoRI sites. 
We realized a strong bias towards small inserts of around 200 bp. The problem was solved by 
introducing a second gel purification step of the PCR products prior to ligation (it also became 
obvious that the planned use of X-Gal based blue/white colony selection was not necessary since 
even the small population of blue E.coli colonies contained inserts). With annealing temperatures 
of 42, 45 and 47 °C, three differently composed subsets of the library were generated. Sequence 
analysis of 50 clones demonstrated that about 50, 85 and 90%, respectively, of the clones in the 
library indeed contained plasmids with protease domain inserts.  
 
 
 
Figure  3.2: The four tested primers are shown. Above the primer sequence, the amino acids encoded 
by the degenerated codons are given (amino acids encoded but not observed in our protease domain 
alignment, are given in brackets). Below the amino acids not encoded by the degenerated primers are 
given followed by a number. The numbers (in percent) indicate that less sequences of the alignment 
harbored this amino acid in the particular position. 
 
 
The library screening was performed in an iterative two-step manner. First, clones were randomly 
selected and submitted to DNA sequencing. Secondly, sequences occurring frequently in this 
selection were used to generate digoxigenin-labeled DNA probes to deselect identical 
clones by colony hybridization. Probes were first tested for crossreactivity on dot-blotted 
plasmids (Figure  3.3). After two rounds of screening six probes were in use (tissue-type 
plasminogen activator, neurotrypsin, hepsin, neurosin, neuropsin and myeloid associated 
differention marker - a non protease sequence encoding the amino acid stretches 
DYTGAAH and GGGGGP separated by 450 bp) that turned out to be applicable in 
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combination, to label all clones containing sequences of the above molecules (Figure  3.3). 
False positive labeling of other sequences was never observed sequencing labeled clones. 
Figure  3.4 gives a flowchart of the library construction and screening process. Our 
screening assessed about 5’000 colonies of which 420 were not labeled and therefore sequenced. 
We found 27 different serine proteases. Interestingly, only eight of these proteases were so far 
described to be expressed in the nervous system, whereas another 18 serine proteases were not 
associated with CNS tissue before. Since the multiple use of the same serine protease in different 
processes was already learned from enzymes such as thrombin, plasmin or tPA, (first known for 
their specific function in blood clot formation/dissolution and meanwhile recognized as players in 
tissue remodeling), it was not unexpected that a sensitive analysis would identify more than the 
previously reported eight serine proteases. Besides the 26 trypsin-like serine proteases listed 
below (Table  3.1) we could identify a clone coding for a formally unknown serine protease. We 
designated this trypsin-like serine protease neurobin (neuronal and Ca-independent like 
thrombin) later on. 
 
 
 
Figure  3.3: Crossreactivity testing of the digoxigenin- labeled probes. A, DNA, as indicated at the left 
margin was blotted onto a nylon membrane and UV-linked. The membrane was incubated with the 
digoxigenin-labeled neurotrypsin probe. Crossreactivity was so low that all probes could be used in 
combination in colony-hybridations (round nylon membranes). As revealed by DNA sequence 
analysis, colonies from black or gray signals only contained sequences corresponding to the probes. 
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Figure  3.4: Flowchart describing the generation and screening of our trypsin-like-protease-domain-
enriched cDNA library. 
 
 
 
Table  3.1: Of the 26 known proteases (from which sequences were found in the library) only the 8 
printed in bold are reported to have a function in neuronal tissue. 
 
3.2  Neurobin full length cDNA cloning and primary 
sequence analysis 
 
Having discovered a cDNA clone encoding the region between His57 and Ser195 of a 
new serine protease we stopped screening the library and focused on molecular cloning of 
hepsin elastase 2 
airway trypsin-like serine protease kallikreinB 
myonase/mast cell protease 4  kallikrein 5 
mast cell protease 5 Kallikrein 1-related peptidase b8 
mast cell protease 8  kallikrein 24  
elastase I tissue-type plasminogen activator 
trypsin 15  neurotrypsin  
acrosin thrombin  
matriptase/epithin plasmin  
complement component factor I neuropsin  
intestinal serine (8) protease neurosin  
neutrophil elastase  transmembrane serine protease 3  
chymopasin spinesin 
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the full length cDNA of neurobin. First we combined the results of several gene 
prediction programs. As confirmed later on, not a single one of the programs available 
online at that time correctly predicted the open reading frame of neurobin over the 
complete sequence length. Since at least the prediction in a segment 5’ to the sequence 
found in the clone from our library was identical with several programs, primers were 
designed that resulted in a PCR product encoding an N-terminally elongated fragment of 
neurobin. The information of the subsequent DNA sequencing allowed designing further 
gene specific primers that were suitable for 5’ RACE. 3’ RACE was performed using 
primers annealing to the neurobin segment initially found in the library. We retrieved 
several 5’ and 3’ RACE-sequences. Finally, using gene specific primers, a clone 
containing an open reading frame of 1293 bp was produced. The corresponding mRNA is 
of at least 1.7kb (Figure  3.5). The encoding gene maps to mouse chromosome 5E3.1. It is 
spread over 10 exons in a 60 kb sequence stretch. The corresponding human gene lies on 
chromosome 4, near q13.  
The open reading frame of the isolated cDNA codes for a protein of 431 amino acids 
(Figure  3.5). It is very likely that neurobin indeed starts with the predicted Met residue, 
since two in frame stop codons, 45 and 30 bp in front of the initiation codon, respectively, 
are present in the 5’-nontranslated part. Thus, neurobin has a cytosolic domain of about 
35 amino acids.  
Hydropathy analysis indicated the presence of a single hydrophobic segment between 
residues 34 and 56 of the amino acid sequence from the longest ORF of the found cDNA. 
This segment was followed by a predicted SEA domain (sea-urchin/enteropeptidase 
/agrin, residues 58 to 183), a short zymogen activation segment (residues 184 to 199), and 
a serine protease domain (residues 200 to 431). Within the protease domain the three 
residues His, Asp, Ser, forming the catalytic triad of serine proteases, were found at 
position 240, 285, and 381, respectively, flanked by amino acids highly conserved in 
trypsin-like serine proteases. Apparently, looking at the motifs around H240 and S381, 
respectively (Figure  3.6, boxed), during PCR with degenerated primers for library 
construction, a single-base misspriming was allowed.  Three consensus motifs for N-
linked glycosylation were identified in the putative extracellular part, one in the SEA 
domain and two in the protease domain. These structural characteristics, together with the 
absence of a hydrophobic signal peptide segment at the N-terminus, provided strong 
evidence that neurobin is a type II transmembrane serine protease. 
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Figure  3.5: Neurobin cDNA and protein sequence and neurobin domain composition. A, The amino 
acid sequence of neurobin deduced from the cDNA sequence is given in single letter code. The 1615 
bp cDNA from 10 (nine coding and one 3’ non-coding) exons on a 60kB genomic segment on mouse 
5E1 contains a 1293bp open reading frame, encoding a protein with 431 amino acids and a calculated 
mass of 48,07 kDa. The predicted transmembrane segment is shaded gray and the zymogen 
activation domain is shaded black. B, Hydropathy analysis of the neurobin protein sequence 
identifies a single hydrophobic segment (gray) close to the N terminus. C, Protein sequence analysis 
by SMART predicts a type two transmembrane protein with a 33 amino acid cytosolic N terminus, a 
transmembrane helix (TM, residues 34-56), an extracellular SEA domain (SEA, residues 58-183), a 
zymogen activation region (ZA, residues 184-199)) and a trypsin-like protease domain (PD, residues 
200-431). Asterisks mark positions of glycosylation motifs. 
 
All members of this family have a short cytosolic N-terminus followed by the 
transmembrane domain. Then come one to several non-catalytic domains and always 
localized at the C-terminus follows the protease domain. In humans this family currently 
consists of 14 members and can be subdivided in 4 subfamilies (Szabo et al., 2003b). The 
best known member of the family is enteropeptidase, which is involved in the initiation of 
the cascade of digestive enzymes. Neurobin belongs to the HAT (human airway trypsin-
like protease)/DESC subfamily of type II transmembrane trypsin-like serine protease 
family (in both human and mouse the neurobin gene lies about 10kb downstream of 
HAT/MAT, suggesting that these two genes might have evolved by gene duplication). 
3.3 Sequence analysis of the protease domain of neurobin 
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Six highly conserved Cys residues were identified in the protease domain (Figure  3.6). 
These Cys residues usually form three disulfide bonds in serine protease domains (C42-
C58, C168-C182, C191-C220, chymotrypsin numbering (Bode et al., 1989)). A seventh 
Cys (C122) could theoretically form a disulfide bond to one of the two Cys residues 
present in the zymogen activation domain, thereby linking stem region and protease 
domain after activation cleavage. A homology search with the protease domain of 
neurobin uncovered highest sequence identities to the protease domains of other TTSPs 
such as DESC1 (58%), HAT (53%), and enteropeptidase (41%). Sequence identity to 
secreted serine protease like tissue-type plasminogen activator, thrombin and factorXa 
was 34-36% (Figure  3.6). 
 
Figure  3.6: Amino acid sequence alignment of the protease domain of neurobin with selected trypsin 
like serine protease domains. The amino acid sequences of the protease domains of human DESC1, 
HAT, bovine enteropeptidase and the human variants of tissue-type plasminogen activator, thrombin 
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and factorXa are aligned to the protease domain of neurobin. All sequences begin with the residue 
following the predicted activation cleavage site. Sequence identities to neurobin are given in percent. 
The numbers above and below the alignment indicate amino acid positions using chymotrypsin 
numbering (Bode et al., 1989)). Numbers at the right margin indicate amino acid numbering of 
each individual protease domain sequence. Boxed in black with white letters are the residues His, 
Asp, Ser, forming the catalytic triad. The six Cys residues giving rise to the disulfide bridges 42-58, 
168-182 and 191-220 are boxed in gray. C122 (boxed) is the residue usually forming a disulfide 
bridge to a Cys residue in the zymogen activation region. D189 (boxed) forms the bottom of the S1 
pocket of serine proteases and determines the preference of Arg or Lys at position P1. Also boxed are 
the highly conserved sequence regions around His and Ser which were used to derive degenerate 
oligonucleotides for library construction. The alignment was generated using ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw/index.html) 
 
  
3.4 Expression of neurobin in mouse tissues 
 
Several lines of evidence suggest that neurobin is expressed at a very low level. First, 
there is no EST database entry till date. Secondly, in the library only three of the analyzed 
clones contained the sequence (in contrast, about every third clone contained cDNA of 
tPA). Thirdly, in PCR with two different specific primer pairs high cycle numbers (>37) 
were necessary to obtain detectable product bands. Fourthly, in all our trails we failed to 
detect neurobin by Northern blot or in situ hybridization analysis, though controls worked. 
Hence, to investigate the tissue expression of neurobin in P10 mice we performed RT-
PCR analysis. As shown in figure  3.7, neurobin was expressed in spinal cord and 
cerebellum. No signal was detected in cortex, heart, kidney, spleen, lung and liver, 
suggesting that neurobin has a rather restricted tissue distribution at this stage. Spinal 
cord of adult mice indicated clear expression of neurobin as well. 
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Figure  3.7: Tissue expression of neurobin in P10 mice. A, cDNA was produced from total RNA from 
P10 mouse tissue using oligo(dT) priming. Only spinal cord was used from P90 animals. The region 
encoding Neurobin C241 to V374 of the protease domain was used for amplification. The PCR 
products were verified by DNA sequencing. B, cDNA quality and amount were controlled in an 
exponential phase PCR reaction using primers for GAPDH. C, Quality of the total RNA preparations 
from P10 tissues is shown on an agarose/formamid gel. DNA molecular mass markers are given at 
the left side in (A) and (B). 
 
3.5 Expression and activation of neurobin in transfected 
HEK293T cells 
 
To study neurobin protein production and zymogen activation, we transiently transfected 
HEK293T cells with neurobin-encoding cDNA vectors. Protein production was tested by 
western blot analysis. Using neurobin-mycHis cDNA for transfection and the anti His 
antibody to detect the C-terminal His tag, we found a doublet signal at 53 kDa, reflecting 
tagged full-length neurobin with a calculated mass of 51 kDa without glycosylation 
(Figure  3.8a). Overexposure of the blot showed a second signal around 30 kDa, 
presumably the tagged protease domain after activation cleavage (not shown, but see 
figure  3.9). With Neurobin-mycHis S381A, a catalytically inactive mutant, only the 53 
kDa product was present (Figure  3.8a). An affinity-purified antibody raised against the 
recombinant SEA domain of neurobin detected the 53 kDa signal as well (Figure  3.8a). 
We next overexpressed untagged neurobin. With neurobin Ser381Ala a doublet product 
at 50 kDa was found, representing full-length untagged neurobin. With overexpression of 
wild-type neurobin, we predominantly detected a product at 23 kDa, but virtually no 50 
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kDa product. None of these signals was found in control samples using empty vector for 
transfection (Figure  3.8a). The 23 kDa product likely represents N-terminal chain 
neurobin without protease domain and, thus, is evidence for efficient (auto-) activation of 
untagged wild-type neurobin in HEK293T cells, whereas activation of tagged neurobin is 
only poorly efficient.  
To test glycosylation of overexpressed neurobin, HEK293T detergent extracts were 
treated with N-glycosidaseF and endoglycosidaseH, respectively. Neurobin was detected 
with the anti SEA domain antibody. The enzymatic treatment resulted in a mass shift of 
about 2-3 kDa of both non-activation-cleaved and of activation-cleaved neurobin (Figure 
 3.8b), indicating that neurobin is subject to N-linked glycosylation in HEK293T cells. 
 
Figure  3.8: Overexpression of neurobin in HEK293T cells. Western blot analysis of neurobin wild-
type and mutant forms in transiently transfected HEK293T cells. A, Detection of neurobin proteins 
with a mycHis tag (wt mycHis, S/A mycHis) reveals a doublet band around 53 kDa. Processing of 
tagged neurobin is only seen after blot overexposure (see B). The affinity purified antibody raised 
against the SEA domain of neurobin gives the same signal. This antibody also reacts with untagged 
neurobin proteins. Wild-type (wt) and neurobin S381A (S/A) are detected as processed 23 kDa and 
unprocessed 50 kDa band, respectively. pcDNA3.1 indicates control transfections with empty vector. 
Molecular mass markers in kDa are given at the left margin. B, Deglycosylation of neurobin. Cell 
extracts used in (A) were treated with N-glycosidaseF and endoglycosidaseH, respectively, before 
electrophoresis and analyzed with the anti SEA domain antibody. The arrows at the right indicate 
the position of the degylcosylated neurobin forms. Molecular mass markers are as in (A). 
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By homology to other serine proteases, activation cleavage of neurobin was expected to 
take place after K199 (Figure  3.5). To test whether neurobin is cabable of self-activation, 
we generated a K199A variant, termed m2, of neurobin-mycHis S381A (designated m1 
in Figure  3.9a). The catalytically inactive mutants m1 and m2 were overexpressed in 
HEK293T cells without or with wild-type neurobin for activation. No protease domain 
was detected upon cotransfection with the empty pcDNA3.1 vector ( 0Figure  3.9b, lanes 
p). Coexpression with wild-type neurobin (Figure  3.9, lanes w) resulted in zymogen 
activation, indicated by the appearance of the mycHis-tagged protease domain (Figure 
 3.9b, PD) in neurobin-mycHis S381A (m1). With K199A (m2), cleavage was reduced, 
but a faint PD signal was still present. However, the full-length signal was strongly 
reduced. This observation led to the hypothesis that neurobin was a protease with self-
shedding, rather than self-activation properties. A supporting hint for the self-shedding 
hypothesis was that for wild-type neurobin in Western blotting with SDS-PAGE under 
non reducing conditions we only detected the 23 kDa product (Figure  3.10c). This was 
surprising since primary sequence analysis had shown that suitable cysteines for a 
disulfide bridge between protease domain and the non-catalytic part of neurobin were 
present. Self-shedding N-terminally of C187 or C188, both candidates for participating in 
link formation, would have been the simplest explanation for our observations. Cleavages 
after K156, K158 and/or K171 were therefore postulated to result in the observed “23 
kDa” signal. To test this postulate, four variants of m1 were generated with alanines 
substituting either one of basic amino acids or all of them. Processing of all these variants 
was not reduced in co-transfections with wild-type neurobin. Therefore we decided to 
analyze the zymogen activation region in more detail. We generated the three additional 
mutants (m3 to m5). In the mutant m3 (R196A, K199A), processing was almost 
completely suppressed and clearly no protease domain signal was detected in the mutant 
m4 which contained no basic residues in the zymogen activation region. Also the 
weakening of the full-length signal intensity was smallest compared to all other mutants. 
Mutant m5, a form carrying the activation site, but containing all other mutations, was 
still cleaved, indicating that the mutations per se did not prevent neurobin from activating 
its zymogen form. The presence of auto-catalytically activated wild-type neurobin was 
confirmed with the anti SEA domain antibody (Fig. 11b, lower panel). These results 
indicate that K199 is likely the sequence-predicted zymogen activation cleavage site. The 
observation that mutant m3 was needed to efficiently suppress the release of the protease 
domain is an indication that possibly in vitro in the mutant forms neurobin can use 
alternative motifs for cleavage. 
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Figure  3.9: A, Mutants m1 to m5 used to identify the zymogen activation site. C, HEK293T cells were 
cotransfected with one of the mutants in the presence of either pcDNA3.1 (lanes p) or wild-type 
neurobin (lanes w). Protein extracts were probed with the anti His antibody. The position of the 
processed protease is indicated by PD. The protease domain is clearly detected in m1 (second lane) 
and in mutant m5 (last lane), but not mutants m2-m4. Presence of wild-type neurobin is shown in the 
lower panel of B. Molecular mass markers in kDa are given at the left margin. 
 
Whether these cleavages can occur in vivo is unknown. However it is not very likely that, 
for instance, cleavage after R196 alone would result in an active protease domain, given 
the observation that predominantly the hydrophobic residues Ile or Val contribute to 
further protease domain stabilization (Song et al., 2002) after activation cleavage. It is 
more likely that alternative sites are used when normal activation is not possible. This 
hypothesis is strengthened by the observation that in co-transfections using mutant m4, 
where no cleavage motifs are present close by, additional signals appear (Figure  3.10a). 
The appearance of these bands in case of only mutant m4 is dependent on the activity of 
neurobin, since they are absent in co-transfections with the S381A mutant of wild-type 
neurobin and weaker in transfections with only half the amount of wild-type neurobin 
(Figure  3.10b). Running behavior and the fact that the signal remains visible under non-
reducing conditions (Figure  3.10c) indicate that in mutant m4, alternative cleavage might 
take place after R224 (preceding the first conserved Cys involved in disulfide bonding 
within the protease domain). R224 is part of the motif VHR which is similar to the 
activation motif GHK199 and the most prevalent substitution motif IHR196. 
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Figure  3.10: Detailed analysis of co-transfections using mutant m4 (transfections as before, 
additionally one co-transfection with the untagged S/A mutant, lane s in B). A, Western blotting 
using the anti SEA domain antibody allowed the detection of m4-specific additional bands (arrow in 
A-C, arrow head in A and B). B, The fragment production is dependent on neurobin activity, since 
absence in co-transfection with the S/A mutant (lane s) and weaker in co-transfections with reduced 
amount of neurobin (lane wp, 1:1 mix of wt-neurobin and empty vector). C, Under non-reducing 
conditions the stronger one of the additional signals remains detectable, indicating alternative 
cleavage N-terminally of C225. Molecular mass markers in kDa are given at the left margin. 
 
All mutants show the same pattern of additional processing within the protease domain 
upon co-expression with wild-type neurobin (Figure  3.11). Fragmentation of the protease 
domain was also observed for the refolded recombinant protease domain of neurobin 
after refolding (chapter  3.8). Intra-domain-cleavages do not necessarily abolish catalytic 
activity as known from chymotrypsin.  
 
 
 
Figure  3.11: Additional processing of the protease domain. Western blotting using the anti tetra His 
antibody revealed additional fragments (PD fragments) running between 15 and 20 kDa in co-
transfections of the mutants with wild-type neurobin (lanes w, co-transfected as before); 15 % 
polyacrylamid gel. Molecular mass markers in kDa are given at the left margin.  
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3.6 Localization of neurobin in transfected HEK293T and 
COS7 cells  
 
Neurobin, with its domain composition predicted to be a type II transmembrane serine 
protease was expected to reside in the ER, Golgi-compartment and/or at the plasma 
membrane. To investigate the subcellular distribution of neurobin, transiently transfected 
HEK293T cells were studied by indirect immunofluorescence analysis. Using neurobin-
mycHis as well as neurobin-mycHis S381A and the anti His antibody, we detected 
immunoreactivity at the plasma membrane of non-permeabilized HEK293T cells (Figure 
 3.12a,d). Immunostaining with the anti SEA domain antibody revealed a very similar 
distribution (Figure  3.12b,e). Untagged wild-type neurobin and neurobin S381A were 
also detected at the cell surface (Figure  3.12g,I less than half the exposure time resulted 
in similar signal intensity as for the tagged variants). Together with the western blot 
analysis these results demonstrate the ability of the anti SEA-domain antibody to detect 
neurobin and support the sequence-predicted topology of neurobin with SEA and 
protease domain on the extracellular side. Because COS-7 cells grow much more 
adherently and flatly than HEK293T cells do, their cell morphology is more 
apprehensive. Therefore, we further studied the subcellular distribution of neurobin by 
indirect immunofluorescence analysis in transiently transfected COS-7 cells. Using 
mycHis-tagged neurobin, double-staining of permeabilized cells with the anti SEA 
domain (Figure  3.13a) and the anti His antibody (Figure  3.13b) revealed ER-like 
intracellular imunoreactivity, respectively. With untagged neurobin the intracellular 
pattern was more Golgi-like (Figure  3.13d) and immunoreactivity on the surface of non-
permeabilized cells was much stronger (Figure  3.13f). 
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Figure  3.12: Cytochemical detection of neurobin in HEK293T cells. Cells were fixed 48hrs after 
transfection. MycHis-tagged (wt mycHis, S/A mycHis) as well as untagged forms of neurobin (wt, S/A) 
are found at the cell surface (A,D,G,I). Tagged neurobin is detected by the anti SEA domain antibody 
as well (B,E).For the anti His antibody, FITC-labeled anti mouse IgGs were used. To visualize the 
affinity-purified anti SEA domain antibody, Cy3-conjugated anti rabbit IgGs were used. Phase 
contrast images are shown in C,F,H,J. Pictures A-J were taken by a LeicaDC300F camera using a 
100x objective.  
 
Taken together, especially the untagged neurobin is efficiently propagated to the cell 
membrane of transfected HEK293T and COS-7 cells. However, most intense 
fluorescence in cells transfected with untagged neurobin was observed in the Golgi-
compartment. This might be explained by the fact, that all neurobin must pass this small 
compartment before it can become distributed all over the plasma membrane. 
 
 
Figure  3.13: Cytochemical detection of neurobin in COS-7 cells. Cells were fixed 24 hrs after 
transfection. For intracellular detection of neurobin, cells transfected with the mycHis-tagged variant 
of neurobin were permeabilized and probed with the anti SEA domain antibody (A) and the anti His 
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antibody (B). Cells display perinuclear, ER-like labelling. Cells transfected with untagged wild-type 
neurobin showed a more Golgi-like labelling pattern (D) and clear surface labelling when probed 
without permeabilization (F). C shows the phase contrast image of A and B, E that of D. Scale bar in 
I: 50 µm (for A to F). 
 
3.7 Histochemical detection of neurobin in mouse CNS 
 
To identify neurobin in vivo we used the affinity-purified anti SEA domain antibody. 
Histochemical analysis of P10 mouse brain sections revealed immunoreactivity in the 
cerebellum (Figure  3.14a), consistent with the RT-PCR analysis. Higher magnification 
indicated that this reactivity was confined to Purkinje neurons, in particular to the cell 
body and to the dendritic tree of Purkinje neurons (Figure  3.14). Preimmun serum 
showed no reactivity (Figure  3.14c). The restricted localization of neurobin is consistent 
with our inability to unambiguously detect neurobin in spinal cord and cerebellar protein 
extracts with our available antibodies, again suggesting that the overall amount of 
neurobin in vivo is fairly low. 
 
 
Figure  3.14: Histochemical detection of neurobin in mouse brain. A, Detection of neurobin in 
horizontal brain sections of adult mice with the affinity-purified anti SEA domain antibody, used at a 
concentration of 3 µg/ml. For visualization Cy3-conjugated anti rabbit IgGs were used. Compared to 
preimmune serum diluted 1:1000, immunoreactivity was confined to the Purkinje cell layer in the 
cerebellum. B, Magnification of the Purkinje cell layer. Only Purkinje cell bodies and their dendritic 
processes are strongly labelled. C, Corresponding region of a brain section incubated with 
preimmune serum. Scale bars in A: 1 mm, C: 50 µm (for B and C). 
 
3.8 Production of recombinant neurobin and enzymatic 
activity 
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To investigate the catalytic potential of neurobin we used a construct encoding an N-
terminal His tag, an enteropeptidase cleavage motif, and the entire protease domain of 
neurobin beginning with V200 and ending with L431. The protein was expressed in E. 
coli, solubilized from inclusion bodies, and purified via Ni-NTA affinity 
chromatography.  
Refolding was tried by either dialyzing against or slow dilution into a wide variety of 
refolding buffers. Conditions under which a significant fraction of the refolded protein 
was present in a soluble monomeric form were detected by centrifugation of the refolding 
sample followed by silver staining after separation on non-reducing SDS-PAGE gels. 
Samples with soluble monomeric protein were concentrated and cleaved by incubation 
with enteropeptidase (EKMax from Invitrogen, overnight at room temperature turned out 
to be the most suitable activation condition). Whenever there was still soluble protein 
present after enteropeptidase incubation, samples were tested for activity using different 
chromogenic peptides. As a positive control the peptides were incubated with trypsin. As 
negative control buffer alone or supplemented with enteropeptidase was used. Using this 
procedure we finally discovered conditions under which active neurobin was generated. 
Careful choice of pH, arginine concentration and the redox system turned out to be most 
critical. Besides, refolding was much more efficient when using slow dilution instead of 
dialysis. Interestingly refolding of the protease domain solubilized in guanidinium 
hydrochloride instead of urea never resulted in active enzyme though we encountered 
conditions under which a significant fraction of protein was soluble after cleavage by 
enteropeptidase. Under optimized conditions the yield was 1.2 % of the protein initially 
purified from inclusion bodies (~ 200 ug active protease domain per liter E.Coli culture).  
 
Silver gel analysis of the purified protease domain revealed a predominant band of 30 
kDa, the non-activated protease domain (Figure  3.15a) after optimized refolding 
conditions. Activation of purified neurobin with enteropeptidase resulted in a new band 
of 27 kDa. Two additional faint bands were detected at the bottom of the gel (Figure 
 3.15a). Under non-reducing conditions the apparent mass of activated neurobin was 
reduced to 24 kDa and the low molecular bands were absent, suggesting that these bands 
are disulfide bridge-linked fragments of recombinant activated neurobin (Figure  3.11). To 
remove enteropeptidase after neurobin activation, MonoS cation-exchange 
chromatography was applied, resulting in homogeneously pure neurobin (Figure  3.15b). 
Size exclusion chromatography indicated that activated neurobin is a monomeric protein, 
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since the protein eluted from a Superdex200 column (23.6 ml volume) at 16.1 ml, very 
similar to chymotrypsinogen (25 kDa, elution at 16.5 ml). 
 
 
 
Figure  3.15: Production of recombinant neurobin. Recombinant neurobin was solubilized from 
inclusion bodies, purified via nickel affinity chromatography and refolded. A, The protease domain 
(hisPD) of neurobin after incubation for 16 h at 37 °C with (+) or without (-)  enteropeptidase 
(EKMax) was submitted to SDS-PAGE either under reducing (r.) or non-reducing (non r.) conditions 
and visualized by silver staining. EKMax removed the 4.6 kDa N-terminal fragment containing the 
His-tag and the enteropeptidase cleavage motif leaving the activated protease domain (actPD). B, 
Further purification of actPD and removal of EKMax by MonoS cation-exchange chromatography. 
400 ng of actPD were resolved by SDS-PAGE and visualized by silver staining. Molecular mass 
markers in kDa are indicated at the left of panels A and B, respectively. 
 
 
3.9 Enzymatic activity of recombinant neurobin towards 
chromogenic peptide substrates 
 
Because Asp is present in the neurobin sequence in position 375 (position 189 in 
chymotrypsin numbering), forming the bottom of the S1 subsite (Hedstrom, 2002), 
acceptance of Arg and Lys in the P1 site was expected. Activated neurobin was used to 
cleave chromogenic peptide substrates in which upon cleavage a paranitroanilde group is 
released, resulting in yellow color accumulating in the buffer. Therefore, cleavage 
efficiency could be measured via the absorption at 405 nm. Neurobin cleaved peptides 
with Arg in position P1 and uncharged residues in positions P2 and P3 (Figure  3.16a). In 
contrast to trypsin, which hydrolyzed all peptide substrates used, neurobin did not accept 
a single Arg residue for cleavage and poor cleavage was measured with Pro in position 
P2. Hardly any cleavage was observed with acidic amino acids in positions P2 and P3. We 
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obtained best cleavage with the peptide Val-Gly-Arg-pNA. The peptide Gly-His-Arg-
pNA, resembling the sequence of the zymogen activation cleavage site (Gly-His-Lys, see  
Figure  3.5), was used for the experiments shown in figures 17b-d. Neurobin had a pH 
optimum around pH 8 (Figure  3.16b), and it was insensitive to a broad range of NaCl 
concentrations (Figure  3.16c), the latter being in accordance with the presence of Pro in 
position 225 (chymotrypsin numbering, (Dang and Di Cera, 1996)). Peptide cleavage by 
neurobin was inhibited by a variety of serine protease inhibitors, but not by E-64, a 
cysteine protease inhibitor, and pepstatin, an aspartate protease inhibitor. Heparin, added 
at two concentrations, did not suppress neurobin activity against peptide substrates 
(Figure  3.16d) and neither the removal of Ca2+ and other divalent cations by EDTA nor 
the extra addition of Ca2+ ions modulated neurobin activity (Figure  3.16d). Ca2+ ion-
independence is consistent with the absence of characteristic acidic amino acids in the 70 
to 80 loop (chymotrypsin numbering) responsible for Ca2+ ion-complexation in other 
serine proteases (Page et al., 2005). 
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Figure  3.16: Specificity of recombinant neurobin against peptide substrates. A. 100 mM of each pNA 
peptide was incubated for 2.3 h at room temperature with either trypsin, neurobin activated by 
EKMax, or EKMax alone. Absorbance was measured at 405nm. Data are derived from two 
independent experiments done in duplicates and expressed as mean±S.D. Values of non-activated 
neurobin and buffer alone, respectively, were identical and below 0.05 absorption units and were 
subtracted before calculating. B, pH optimum of recombinant neurobin. 250 mM GHR-pNA was 
incubated for 2 h at 30°C with purified activated protease domain in 20 mM phosphate buffer 
(dashed line) and 20 mM Tris-HCl buffer (solid line) at the pH values indicated. Measurements were 
done in triplicate and are represented as mean±S.D. The pH-test was repeated once with the well 
cleavable peptide Phe-Val-Arg-pNA to confirm that His in P2 was not responsible for low neurobin 
activity at low pH. C, Activity of neurobin in the presence of increasing concentrations of NaCl. 
Experimental conditions were as in (B) with 20 mM Tris-HCl buffer pH 8.0. D, Suppression of 
neurobin proteolytic activity. Measurements were done in triplicate and are represented as 
mean±S.D. 
 
Since we did not determine the percentage of catalytically active molecules in the 
purified preparations of refolded neurobin, we did not attempt to determine kinetic 
parameters but simply checked that the reactions never reached a plateau during activity 
assays. 
 
 
 
Figure  3.17: Example for reaction control-monitoring. Shown here is one of the datasets used for 
figure 17d.  
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3.10  Catalytic activity of recombinant neurobin towards 
protein substrates 
 
Several previously identified TTSPs substrates were recruited among extracellular matrix 
components, cell surface molecules and growth factors. Therefore, to identify potential 
protein substrates of neurobin we incubated fibronectin, laminin, FGF-7, and FGF-2 with 
trypsin and recombinant neurobin, respectively. All substrate proteins were degraded by 
trypsin, whereas neurobin did not cleave the large extracellular matrix proteins 
fibronectin and laminin, or the growth factor FGF-7 (Figure  3.18a). Neurobin, however, 
selectively processed FGF-2. This cleavage resulted in the formation of a 13 kDa and 
further fragments (Figure  3.18a and b). Since FGF-2 has strong heparin binding 
properties (Moscatelli et al., 1987), we wondered whether the presence of heparin in 
concentrations used during the peptide cleavage assays modulated FGF-2 processing by 
neurobin. In the presence of heparin FGF-2 cleavage by neurobin was suppressed in a 
dose-dependent manner (Figure  3.18a). A more detailed analysis of the FGF-2 cleavage 
showed that neurobin processed FGF-2 to at least three major fragments. Cleavage 
occurred after Lys or Arg residues, as deduced from sequence analysis of the cleavage 
products (Figure  3.18b). Fragments 1a, b and 4a begin with the N- terminus of 
recombinant human FGF-2. All other fragments start after a basic amino acid preceding 
the cleavage site. Cleaved FGF-2 was also analyzed by MALDI-TOF-MS. Average 
masses of 12794.0, 8581.8 and 4348.8 were detected. These masses reflect the theoretical 
masses of A2-R116 (12792, Figure  3.18b, fragment 1a), I43-R116 (8517.6, Figure  3.18b, 
fragment 2) and S117-S154 (4349.1, Figure  3.18b, fragment 5a). Together with the 
peptide substrate assays, these enzyme activity experiments demonstrate that neurobin is 
an authentic serine protease with amino acid preference for Arg or Lys in the P1 position 
and, possibly, very selective protein substrate specificity.  
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Figure  3.18: Activity of recombinant neurobin towards protein substrates. A, 200 ng of fibronectin, 
laminin, FGF-7, and FGF-2, respectively, were incubated for 4 h at 37°C with either buffer (-), 2 ng 
neurobin (N) or 2 ng trypsin (T). The reaction was stopped by the addition of loading buffer. Samples 
were resolved by SDS-PAGE and proteins visualized by silver staining. With the exception of FGF-7, 
all proteins were almost completely degraded by trypsin. N and T at the right margin indicate the 
protease in the reaction mixture. The arrow indicates the position of the 13 kDa fragment of FGF-2. 
Molecular mass markers are given in kDa at the left margins. B, FGF-2 was digested as in A. 10% of 
the reaction were used for silver gel analysis on a 4-12 % NuPAGE gel. N and F at the right margin 
indicate recombinant neurobin and full-length FGF-2, respectively. The rest of the reaction was 
identically resolved and the proteins transferred onto a PVDF membrane. Bands 1 to 5 were 
analyzed by Edman degradation. Whenever the sequence did not begin with the N-terminus of 
recombinant human FGF-2 the last three amino acids preceding the cleaved peptide bond are given 
in the grey box with position number of the P1 residue. 
 
3.11  Trials to investigate FGF-2 cleavage by neurobin in cell 
culture experiments. 
 
Interestingly, histochemical localization of FGF-2 in the cerebellum revealed strong 
expression in Purkinje cells with a distribution very similar to the distribution of neurobin 
(Reynolds et al., 2005), indicating that FGF-2 could indeed be an in vivo substrate of 
neurobin. To obtain further evidence for this hypothesis we tried to observe FGF-2 
cleavage by neurobin in cell culture experiments. Thus, we first cloned FGF-2 from 
spinal cord cDNA from P10 mice. Since FGF-2 is secreted via an alternative ER-/Golgi-
independent secretion pathway we cotransfected cells with neurobin and FGF-2 
containing expression vectors and analyzed the cell extracts and the culture media by 
SDS-PAGE/Western blotting. In our first attempts we expressed FGF-2 with a C-terminal 
ONEstrep tag variant. C-terminal tags are reported not to interfere with efficient secretion 
by the alternative pathway (Florkiewicz et al., 1995). However, in HEK293T and COS-7 
cells our construct, though well expressed, could hardly be detected in the cell media 
(Figure  3.19a). 
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Figure  3.19: A, Western blot analysis of extracts and media of HEK293T cells, co-transfected with 
mouse FGF-2 fused to a C-terminal ONEstrep tag (FGF2strep) and either pcDNA-vector (p), wild-
type neurobin (w) or the S/A mutant thereof (s). Streptactin linked to horseradish peroxidase allowed 
detection of FGF-2 wherever expected (though very little could be detected in the medium). The most 
right blot in A is the same as shown on the left, reprobed without stripping using the anti SEA 
domain antibody. The SEA domain stump resulted in a band running a little higher than the 
ONEstrep-tagged FGF-2. A weak band could be detected resulting from the full-length S/A mutant 
of neurobin (fl). B, Silvergel of recombinant human FGF-2 was incubated with only buffer (B), 
neurobin (N), neurobin plus 10 µg/ml heparin (N+H) or trypsin (T) as before. Additionally this time 
FGF-2 was incubated with trypsin plus 10 µg/ml heparin (T+H). Heparin strongly protects FGF-2 
also from digestion with trypsin. Molecular mass markers in kDa are indicated at the left of panel A 
and B. 
 
Purifying the strep-tagged FGF-2 from the medium of co-transfected HEK293T cells via 
Magstrep magnetic beads, we could not find any processed FGF-2. From a control 
experiment we learned that the cleavage of FGF-2 by trypsin can be inhibited by the 
addition of heparin too (Figure  3.19b). 
With a commercially available anti FGF-2 antibody which recognized FGF-2 fragments 
from an in vitro digest with neurobin (Figure  3.20a), we repeated the experiments with 
untagged FGF-2. Secretion efficiency was still low and no cleavage could ever be 
detected in the medium (Figure  3.20a). Therefore we introduced FGF-2 into the normal 
secretory pathway by fusing the secretion signal of human calsyntenin 1, a type I 
transmembrane protein, to the N-terminus. The protein was expressed but also not 
secreted and no cleavage of FGF-2 could be detected in the cell extracts (Figure  3.20c). 
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Figure  3.20: Westernblot analysis of (C-terminally) untagged FGF-2 variants in cotransfections. A, 
The proteins from media of HEK293T cells, co-transfected with mouse FGF-2 and either pcDNA-
vector (p), wild-type neurobin (w) or the S/A mutant thereof (s) were precipitated with the Wessel-
Flücke method and analysed by western blotting using the affinity-purified anti FGF-2 antibody 
purchased from Prepotech. In the first three lanes the equivalent of 300 µl medium and in the second 
three lanes the equivalent of 50 µl medium were loaded. In the last lane the partial digest of 50 µg 
human FGF-2 (hFGF-2, from Invitrogen) was loaded as a control for blotting and antibody quality. 
Clearly the dimer, monomer and the 13 kDa fragment were detected as strongest bands. B, 
Reprobing the first three lanes of the blot shown in A (without stripping) with the anti SEA domain 
antibody resulted in the detection of the transmembrane stump containing the SEA domain. This 
suggested that cell disruption was at least partially responsible for the FGF-2 signal. C, Western 
blotting using the extracts of HEK293T cells co-transfected with mouse FGF-2 fused to an N-
terminal calsyntenin secretion signal (sCstF) was performed with a mixture of the affinity-purified 
anti FGF-2 and the anti SEA domain antibodies. Full-length neurobin and activated neurobin as well 
as uncleaved FGF-2 could be detected. Molecular mass markers in kDa are indicated at the left of 
panel A and C. 
 
In a control experiment we were surprised to realize that DMEM without FCS, used as 
cell culture medium, reduced cleavage efficiency of neurobin towards the peptide 
substrates. To rule out the detrimental effect of the medium, we switched back to the co-
transfection experiments in COS-7 cells using the untagged FGF-2, and, one day post 
transfection removed the medium, washed the cells with PBS and kept them in the 
incubator in PBS for 6 hrs. In the subsequent analysis of the PBS supernatant we detected 
small amounts of FGF-2. However, also after incubation in PBS no processing could be 
detected. The finding that irrespective of the used secretion pathway well detectable 
amounts of FGF-2 were found intracellularly, but only minimal amounts were secreted, 
suggested that FGF-2 might adsorb to the plasma membrane. To test this idea, 
immunofluorescence was performed. Indeed, using transiently transfected COS-7 cells, 
FGF-2 immunoreactivity was detected at the plasma membrane (Figure  3.21). From the 
outcome of our experiments and given the heparin binding properties of FGF-2 we 
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assume that FGF-2 binding to proteoglycans from the cells is responsible for both, 
difficulties to detect FGF-2 in the medium and our failure to observe its cleavage by 
neurobin in the cell-culture system. 
 
 
 
Figure  3.21: Imunnofluorescence pictures of COS7 cells transfected with mouse FGF-2. For detection 
the affinity-purified anti FGF-2 antibody 2 µg/ml was used in combination with the goat anti rabbit 
Cy3 1:500. The antibody incubation steps were performed in the presence (A) or absence (C) of 0.1 
% saponin for permeabilization. B shows the phase contrast picture of A, D that of C. The scale bar 
in D is 50 µm. 
 
 
3.12  Supplementary experiments and results 
 
3.12.1  Peptide antibody raising, affinity purification and testing  
 
The first 22 aminoacids of neurobin (intracellular part, MARGQPRRSEEQWTALQNR-
TEC) coupled to keyhole limpet hemocyanin via Cys22 were used to immunize two 
rabbits at Primm (Italy). The resulting antisera R134 and R135 recognized the antigen 
well, but only when dot-blotted on a nitrocellulose membrane under native conditions 
(Figure  3.22a). Both R134 and R135 recognized neurobin in transfected HEK293T cells 
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only in immunofluorescence experiments but not in Western blotting. Taken together, 
this suggests a secondary structure motif epitope (secondary structure analysis programs 
predict a short N-terminal coil followed by an alpha helix). The sera were functional in 
immunofluorescence using HEK293T cells transfected with mycHis-tagged neurobin. 
However, using the sera for histochemistry experiments with P10 cerebellum and spinal 
cord sections, no signals were obtained that were not present with the preimmun sera 
taken as controls. Next, the peptide antigen was coupled to NHS-activated sepharose for 
affinity purification of the antibodies after ammonium sulfate precipitation and dialysis. 
Affinity-purified R134 and 135 showed much reduced background staining in 
immunofluorescence. However, the signals were still weaker than obtained with the anti 
tetraHis antibody (costainings) and affinity purification did not improve the situation for 
Western blotting and histochemistry.  
With the result from our dot-blot experiments in mind, we thought that the antibodies 
might be functional in affinity purification of neurobin from extracts of transfected 
HEK293T cells. Therefore, we coupled the affinity purified R134 to NHS-activated 
sepharose. Indeed in subsequent batch purifications we were able to purify the 
noncatalytic part of wild-type neurobin from extracts of transfected HEK293T cells 
(Figure  3.22b). Using the same experimental conditions with P10 cerebellum extracts 
neurobin could not be affinity purified (Figure  3.22c). Taken together, the peptide 
antibodies worked under certain conditions. But since the affinity was low, the small 
amounts of neurobin expected in mouse tissues could not be detected or purified using 
this peptide antibody. An alternative or ancillary explanation could be that the cytosolic 
epitope might be shed off or destroyed by posttranslational modifications (e.g. sequence 
analysis by NetPhos2.0 predicted that Ser9 in this domain is embedded in a motif suitable 
for Ser/Thr phosphorylation. We do, however, not know, whether neurobin is indeed a 
kinase substrate in vivo) and thus renders the peptide antibody worthless for the analysis 
of the physiological situation. 
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Figure  3.22: Trials to use the peptide antibody R134 directed against the cytosolic segment of 
neurobin. A, When dot-blotted onto a nitrocellulose membrane, the antigen was detected more than 
10 times better when prior solubilized in water than when prior solubilized in Lämmli buffer. B, 
Western blotting (SEA domain antibody) monitoring the affinity-purification of the non-catalytic 
part of activated neurobin from extracts of transfected HEK293T cells via purified peptide 
antibodies coupled to NHS-activated sepharose. The purification was done in parallel for vector (-) 
and neurobin (+) transfected cells (extr.: loading, FTh: flow through,W: wash, E, elution; the resins 
were boiled after the purification – elution was complete, only IgG heavy and light chains detectable). 
C, The same purification using extract from P10 mouse cerebellum did not allow the detection of 
neurobin. 
 
In the second approach we raised antibodies against a peptide of the protease domain of 
neurobin. We chose the peptide L258 to I271 (LLSKPQAPRAVKNI) as antigen, 
preceded by a cysteine for coupling to keyhole limpet hemocyanin. Peptide synthesis, 
coupling and immunization of two rabbits and two guinea pigs was performed at Pineda 
(Berlin). Third boost antisera of all animals and fifth boost antisera of the rabbits were 
tested in cytoimmunofluorescence and Western blotting using transfected HEK293T 
cells. Expression of myc-his tagged neurobin was confirmed with the tetraHis antibody in 
each experiment. In cytoimmunofluorescence at a dilution of 1:200, the rabbit peptide 
antiserum R1 produced very weak specific signals, but high background. No specific 
signals were detected in Western blotting, when testing the peptide antisera in dilution 
series ranging from 1:100 to 1:30’000.  
Antiserum R1 was affinity-purified using the antigen coupled to NHS-activated 
sepharose. Affinity purification strongly reduced the background reactivity in 
immunofluorescence. In Western blotting, affinity-purified R1 was still not functional. In 
transfected cells neurobin immunoreactivity could be detected when fixed with PFA (and 
permeabilized with saponin) or methanol/aceton. In histochemistry, using PFA-fixed 
horizontal brain sections the affinity purified R1 at a concentration of 20 ug/ml resulted 
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in weak labeling of Purkinje cell bodies. In controls the R1 preimmune serum was used in 
a dilution of 1:100. At this concentration also the preimmune serum resulted in labeling 
of Purkinje cells. In methanol/aceton fixed brain sections the labeling caused by the 
affinity purified R1 disappeared completely while the staining caused by the preimmune 
serum remained detectable. The discrepancy between cyto- and histchemistry is difficult 
to explain. The fact that the fixation method did not influence reactivity of R1 in 
cytochemistry suggests that it was not the thechnique per se causing the disappearance of 
the specific signal in histochemistry after methanol/acetone fixation. Besides, comparing 
the immunofluorescence intensity of affinity purified R1 to that of the anti tetraHis 
antibody, it became apparent that this antibody was probably of lower affinity than the 
affinity purified R134. 
 
3.12.2 Eukaryotic antigen production in HEK293T cells 
 
Parallel to the peptide antibody approach we worked on the production of protein 
antigens. In our laboratory eukaryotically produced proteins have resulted in much better 
immune responses than prokaryotically produced antigens (possibly, because eukaryotic 
posttranslational modifications increased antigenicity or because the modification simply 
rendered the antigen mor similar to the target protein). The idea was to obtain the protein 
of interest in the supernatant of transfected cells. All generated constructs coded for an N-
terminal secretion signal (from neuroserpin), then an Fc-tag and a subsequent PreScission 
cleavage motif. There was a MycHis-tag for detection at the C-terminus of each construct. 
Between the tags we icluded the whole extracelullar part of neurobin (FcSEAPDmycHis), 
only the SEA domain (FcSEAmycHis) and only the protease domain (FcPDmycHis), 
respectively.  Initially it was planned to produce recombinant proteins without the C-
terminal tag, once expression and purification were optimized (using protein A-Sepharose 
and elution by on column cleavage of the Fc-tag by PreScission would have resulted in 
tag-free recombinant protein). The possibility to obtain correctly folded and 
posttranslationally processed enzyme for activity assays made eukaryotic expression an 
attractive dual purpose approach. All three constructs were well expressed in HEK293T 
and COS-7 cells. Immunofluorescence with transfected COS-7 cells revealed marked 
differences in subcellular protein distribution. The FcSEAmycHis construct showed 
accumulation in a well defined Golgi-like area (Figure  3.23a). FcSEAPDmycHis and 
FcPDmycHis resulted in a scattered, network-like (ER-like) fluorescence (Figure  3.23b). 
Additionally, a perinuclear accumulation of fluorescence was observed in constructs 
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where the transmembrane domain of neurobin was present (Figure  3.23c). Only the 
construct without protease domain was secreted efficiently by transfected HEK293T and 
COS-7 cells. Therefore, FcSEAmycHis was purified from the supernatant (75 ml per 500 
cm2-plate) of transfected HEK293T cells. Purity was considered insufficient for 
immunization after protein A affinity chromatography. Therefore the C-terminal tag was 
maintained and used for a second chromatography step using immobilized metal affinity 
chromatography (HisSelect, an agarose bead resin with nickel chelate). This procedure 
allowed the production of pure antigen. Two rabbits were immunized in house with 30 ug 
mycHis-tagged SEA domain for both initial immunization and boosts.  
 
Figure  3.23: Imunofluorescence pictures of COS7 cells transfected with the eukaryotic expression 
constructs or wild-type neurobin. All constructs contained the C-terminal mycHis tag. Red 
fluorescence was obtained from the incubation with the anti SEA domain antibody after affinity-
purification in combination with the donkey anti rabbit Cy3 antibody. The green fluorescence was 
obtained from the combination of the anti tetra His antibody with the goat anti mouse FITC antibody. 
Models of the constructs are shown below the pictures (Ns: neuroserpin secretion signal, Fc: Fc-tag). 
A, only the SEA domain construct is efficiently propagated in the secretory pathway, as seen from 
clear staining of the Golgi compartment. B, The constructs containing the tagged protease domain of 
neurobin remained in the ER network (example of the construct containing both, the SEA domain 
and the protease domain of neurobin is depicted). C, The tagged wild type neurobin containing the 
transmembrane segment appeared to be enriched in the ER close to the nucleus. 
 
Results 61 
3.12.3 Testing and affinity purification of the SEA domain 
antibody using the prokaryotically expressed SEA domain 
 
Both first and second boost sera of both rabbits (R143 and R145) recognized the antigen 
and could be used both for immunofluorescence and Western blotting (though high 
background was observed). For affinity purification the SEA domain (Ala55 to Lys199) 
was produced with N-terminal His-tag in E.coli strain BL21CodonPlus(DE3)-RIL using 
the pET-expression system (Figure  3.24a). After affinity purification on HisSelect 
(Figure  3.24b), 50 mg of soluble SEA domain were obtained from 1 liter of E.coli culture.  
 
Figure  3.24: A, Coomassie gel analysis of E.coli clones overexpressing the SEA domain. A significant 
fraction of both, the short SEA domain (stopping in front of the two Cys in the zymogen region, 
SEAdCC) and the full length SEA domain (SEA) were expressed as soluble proteins upon induction 
with 1 mM IPTG (+). B, Silver stained polyacrylamid gel monitoring the purification of the soluble 
full length SEA domain. In lanes 7 and 8 were loaded with 1 µg protein from two different elution 
fractions.  
 
The purified SEA domain was coupled to NHS-activated sepharose and used for affinity 
purification of the antibodies. This significantly improved the signal to background ratios 
in both Western blotting and immunofluorescence and rendered the anti SEA domain 
antibody an important tool (Figure  3.25 and preceding result sections). 
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Figure  3.25: Affinity-purification resulted in a dramatic effect on the performance of SEA domain 
antibodies. Horizontal sections of a P10 mouse cerebellum were submitted to histochemistry using 
either the first boost serum of R143 in a dilution of 1:10 (A) or affinity purified IgGs of the second 
boost of R143 at a concentration of 3 µg/ml (B). 
3.12.4 Antibodies against the protease domain from antigen 
refolded and purified from E.coli inclusion bodies 
 
Since recombinant proteins containing the protease domain were not secreted by HEK 
293T and COS-7 cells, we tried to find conditions allowing the soluble expression of the 
protease domain in E.coli. Since we never found suitable conditions (Figure  3.25a), we 
decided to use the protease domain refolded from inclusion bodies (Figure  3.25b).  
The His-tagged protease domain was purified under denaturing conditions on HisSelect 
from washed inclusion bodies solubilized with guanidinium hydrochloride. Silverstaining 
revealed one very strong band of the expected size and additionally weak bands of 
smaller proteins when separating 3 ug of the eluted material by reducing SDS-PAGE. 
Like the strong band, the small bands were also detected in Western blotting using an 
antiHis antibody and were therefore considered to be N-terminal fragments of the 
protease domain. 
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Figure  3.26: Coomassie stained gels showing an example of conditions tested for soluble protease 
domain (PD) expression. A, Extracts of E.coli cultures displayed the same band pattern independent 
whether IPTG was used for induction or not. B, In contrast, the inclusion body fractions of induced 
cultures showed a strong accumulation of a band running at the expected height. Labels of the 
molecular mass markers in kDa are indicated at the left of panel A. 
 
Refolding trials eventually led to a soluble protein fraction. Non-reducing SDS-PAGE 
revealed a heterogeneous population of oligomers (in assays with chromogenic peptide 
substrates no activity was observed in these refolding samples after processing by 
enteropeptidase). The refolded material was purified on a HisSelect column using native 
conditions. As expected, the low molecular weight bands were co-purified (Figure  3.26a). 
MS-fingerprint analysis indeed proved them to be N-terminal fragments of the 
recombinat protease domain of neurobin. Thus, the material fulfilled our quality criteria 
and was used to immunize two rabbits. 
The sera (R156 and R158) of the first and second boost were analysed. They performed 
weak in Western blotting with neurobin transfected HEK293T cell extracts, and were not 
functional in immunofluorescence experiments. From a Western blot analysis we learned 
that most immunoreactivity was caused by the N-terminal segment of the antigen which 
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is not part of neurobin (Figure  3.26b). Therefore, we did not inject further antigen into 
animals.  
 
Figure  3.27: A, Reducing silvergel (r.) and Western blot (WB, with anti tetra His antibody) analysis 
of the refolded protease domain of neurobin (hisPD) after native HisSelect chromatographie. In both 
cases 1 µg protein was separated on 12.5 % polyacrylamide gels. The monomeric form of hisPD 
resulted in the strongest signals (in WB luminescence substrate was locally depleted). Since reduction 
was not quantitative, the dimer and in the case of WB also tri- and tetramer could be detected. 
Additional bands were detected below the monomer, both in silver staining and Western blotting. B, 
The second boost antibodies raised against the hisPD antigen were tested on 9 ng hisPD (1) and 18 ng 
PD after activation (as presented on the silver gel).From densiometric analysis we learned that the 
antigen with the His-tag, linker and enteropeptidase cleavage site present was recognized 3 and 10 
times better respectively than the activated protease domain. Molecular mass markers in kDa are 
indicated at the left of panel A and B. 
 
 
3.12.5 Potential of polishing the protease domain 
 
To obtain an even more homogenous fraction of the correctly refolded neurobin protease 
domain ( 3.8) without the low molecular bands being present (e.g. for kinetic studies or 
crystallization attempts) a benzamidine column can be used (Figure  3.27). However in 
our trials binding was incomplete and the absence of the low molecular bands might in 
part be explained by the low amount of protein submitted to the silver staining analysis 
after such a polishing step. 
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Figure  3.28: Silvergel analysis of the benzamidin-column purification of either the activated protease 
domain (Activated PD) or the protease domain prior to activation by enteropeptidase (Dialysed PD). 
A, The smear of ill-folded oligomers visible in the loading sample (L), was detected in the 
flowthrough (FTh) and wash fractions. As expected, only activated protease bound to the column and 
could be recovered in elution fractions (E1-3). B, Reducing conditions revealed that molecules 
without intradomain cleavage bind best to benzamidine. Labels of the molecular mass markers in 
kDa are indicated at the left of panel A. 
 
3.12.6  Trials for periplasmic expression of the protease domain 
and the SEA domain in E.coli 
 
As the formation of correct disulfide bridges might occur in the oxidizing environment of 
the bacterial periplasm, the DNA sequence of neurobin SEA or protease domain with C-
terminal mycHis tag was ligated in frame to the N-terminal PelB periplasmic secretion 
signal in the pET20b+ vector. In all the tested expression conditions in E.coli strain 
BL21CodonPlus(DE3)-RIL, the recombinant proteins were only detected in the inclusion 
body fraction, but not in the soluble or periplasmic fraction, nor in the medium. 
Obviously the hydrophobic PelB sequence was unable to ensure secretion but led to 
aggregation of even the SEA domain which as such was highly soluble (see Figure  3.24). 
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3.12.7  Trials for expression in pichia pastoris strains  
 
Yeast is a well established organism for the production of secreted proteins. The Pichia 
pastoris expression system offers both the benefits of E. coli (high-level expression, easy 
scale-up, and inexpensive growth) and the advantages of expression in a eukaryotic 
system (protein processing, folding, and posttranslational modifications). Besides, the 
glycosylation in Pichia pastoris is said to differ less from higher eukaryotes than the 
glycosylation in Saccharomyces cerevisiae (less hyperglycosylation, high mannose with 
only 8-14 mannose residues compared to 50 -150 in Saccharomyces cerevisiae, no alpha 
1-3 glycan linkages). We therefore expected to obtain efficient protein secretion by 
producing recombinant proteins with N-terminal Saccharomyces cerevisiae alpha-factor 
(introduced by pPICZα vectors) in Pichia pastoris. 
All generated constructs contained an N-terminal yeast signal peptide sequence. One of 
the constructs encoded the protease domain with N-terminal His-tag and enteropeptidase 
cleavage motif. Two other constructs (SEA from Ala55 to Lys199 and SEA plus protease 
domain from Ala55 to Leu431) were cloned with a C-terminal mycHis tag. Protein 
production from the three constructs was tried in the Pichia pastoris strain X-33, 
recommended when using the pPICZα vector, but also strains GS115 and KM71H 
following the instructions in the EasySelect Pichia Expression manual 
(http://www.invitrogen.com/content/sfs/manuals/easyselect_man.pdf). Growth conditions 
and methanol-induced gene expression under the AOX1 promotor were suitable for 
secretion as controlled with a GS115 mutant overexpressing human albumin under the 
AOX1 promotor as proven by the fact that in general, the albumin signal was observed in 
the supernatant by a simple Ponceau S staining already two days after induction start 
(Figure  3.29 a). The SEA and the protease domain constructs were expressed well in all 
strains as observed by performing Western blot analysis with extracts from induced yeast 
cultures (Figure  3.29 b). However, the supernatant of such cultures did not contain 
recombinant protein detectable by Western blotting at any time point of eight-day 
induction periods.  
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Figure  3.29: Example of the yeast expression trials. A, The human serum albumin signal was 
detectable in the medium by day 2 (d2) by Ponceau S staining when incubating an HSA secreting 
GS115 strain clone. The protease domain of neurobin (PD) could never be detected in the medium by 
Western blotting, testing 21 different clones. B, Extracts of several KM71H and X-33 clones showed 
clear expression of the PD (upper of the strong bands likely resulted from the protease domain with 
the signal sequence not cleaved off) after 3 days in culture. Detection was performed using the anti 
tetra His. Molecular mass markers in kDa are indicated at the left of panel A and the right of panel 
B. 
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4 Discussion 
 
In summary, our work enabled the identification and biochemical characterization of a 
new TTSP, designated neurobin/TMPRSS11c. Neurobin has a short cytosolic N terminus, 
a single transmembrane domain, an SEA domain and the C-terminal protease domain. 
With this domain organization, neurobin mostly resembles the members of the 
DESC/HAT group of TTSPs. The protease has a restricted tissue distribution with 
prominent presence in Purkinje neurons. In vitro, neurobin is able to process FGF-2 after 
several basic residues, but it does not cleave extracellular matrix molecules such as 
laminin and fibronectin. Further analysis is needed to assess the in vivo relevance. 
 
4.1 The insensitivity of neurobin towards calcium and 
sodium ions 
 
Neurobin activity was not modulated by Ca2+ ions. As recently reviewed (Page et al., 
2005), allosteric regulation of serine proteases is mediated via Ca2+ complexation by 
acidic amino acids in position 70 and 80 (chymotrypsin numbering). In neurobin, Phe and 
Leu, respectively, are present, consistent with the insensitivity of neurobin toward 
calcium concentration changes. Using a broad range of Na+ concentrations for the peptide 
cleavage assays, we measured no significant differences in the catalytic activity of 
neurobin, suggesting that this enzyme is not allosterically regulated by Na+ ions. With 
respect to allosteric regulation, site-directed mutagenesis with thrombin revealed that 
residue 225 (either Tyr or Pro in serine proteases) is implicated in Na+-induced regulation 
of enzyme activity, because thrombin Tyr225Pro (chymotrypsin numbering) lost its 
ability to bind Na+(Dang and Di Cera, 1996). In neurobin, Pro412, i.e. the residue 
compatible with Na+ insensitivity, occupies the homologous position. Pro412 is 
embedded in the sequence Asn-Lys-Pro-Gly. The entire motif is conserved in all 
DESC/HAT-like enzymes, a further point suggesting a relationship among these 
enzymes. 
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4.2 The neurobin locus and neurobin preservation in other 
species 
 
Using neurobin cDNA sequences our gene bank homology searches indicated that the 
neurobin gene lies on mouse chromosome 5. This region was recently described as a 
locus containing seven DESC and HAT-like TTSP genes in a cluster (Hobson et al., 
2004). These authors also predicted the existence of neurobin (referred to as HAT-like 3). 
However, the protein sequence predicted from genome analysis was not fully identical to 
our cDNA-derived sequence (predicted length 418 amino acids, resulting from the 
absence of 13 amino acids forming the end of the SEA domain and the zymogen 
activation part). Sequence predicions revealed that these 13 amino acids are present in 
horse and short-tailed opossum, but absent in rat, dog, and cow. The relevance of this 
difference is, however, not known. Five of these DESC and HAT-like genes could be 
identified on human chromosome 4 (Hobson et al., 2004). Our gene bank homology 
analysis and own sequencing of human genomic DNA indicated that the predicted last 
exon in the genomic region, possibly encoding a human orthologue, contained an eight 
base-pair insertion shortly after the triplet encoding the catalytic S381. The insertion 
leads to a completely unrelated amino acid sequence after I393 and e.g. the loss of C406, 
mandatory for one of the three conserved disulfide bonds. The concerning sequence 
stretch is also forming part of the cavity of the catalytic triad and the S1 pocket (Figure 
 4.1). There is little chance that the resulting sequence would allow the assembly of a 
functional protease domain. Besides, the exons encoding a possible SEA domain of 
human neurobin can not be assigned. Taken together it is very likely that the human 
neurobin gene is completely psydogenized. More and more genomes were completed till 
date. The neurobin gen appears functional in rat, horse, dog, cattle, gray short-tailed 
opossum and possibly also in the platylus genome. Till date however, in the genomes of 
chimpanzees and macaques neurobin can not be assigned.   
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Figure  4.1: The ribbon model of the neurobin protease domain sequence is shown after alignment to 
the 3-D template (built by the overlay of the x-ray structures of four trypsin-like serine proteases 
from the PDB: 1ekb(B) - bovine enteropeptidase, 1eax(A) – human matriptase, 1z8g(A) – human 
hepsin and 2any(A) – human plasma kallikrein), chymotrypsin numbering with selected residues. 
Neurobin is colored in green until I393 and then in red until the C-terminus. The red part contains 
C220, P225 and contributes to the formation of the catalytic center and the S1 pocket. From the 
enteropeptidase structure the conserved disulfide bridges are shown in yellow and other selected 
residues in blue. Neurobin residues are depicted in black. The orientation of the 70 to 80 loop, 
associated with Ca2+ allostery, differs most comparing the enteropeptidase structure and the 
neurobin model (the ribbon model of enteropeptidase residues 70 to 84 is given in magenta). B, 
Stereo image, same orientation as in A. The D189 is clearly visible at the bottom of the S1 pocket. 
 
4.3 Implications of neurobin-absence in man 
 
A possible absence of neurobin in man does not exclude the absence of its function. The 
high sequence identity of the neurobin protease domain to the protease domain of the 
members of the highly related DESC/HAT group could have enabled one of these 
enzymes to take on proteolytic specificity and function in man similar to the one of 
neurobin in mouse. Such a concept is compatible with the finding that DESC2 (Netzel-
Arnett et al., 2003) and DESC4 (Behrens et al., 2004) are expressed in human brain 
tissue. Human DESC1 can cleave fibronectin (Viloria et al., 2007), a protein not cleaved 
by neurobin. This points to not exactly neurobin-like specificity, despite the fact that 
DESC1 has highest homology to neurobin. Alternatively, a human protease with 
neurobin-like function might have remote homology only, as recently observed with the 
identification of the murine metalloprotease Mcol-1, a possible counterpart of human 
MMP-1 (Balbín et al., 2001). Finally, genomic analyses indicate that man and mouse 
share some 166 serine protease genes, whereas nine are human specific and 43 are mouse 
specific (Puente et al., 2003b). Hence, molecules present in one species only may be 
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instrumental in highly species-specific functions. Or, to stress another aspect of the same 
story: Neurobin might be one of the gene products leading to the manifestation of 
differences between mammals like mice and men.  
 
 
4.4 Selfactivation of neurobin 
 
Autoactivation has been described for other TTSPs (Afar et al., 2001; Guipponi et al., 
2002; Szabo et al., 2005; Velasco et al., 2002). Catalytic activation of Neurobin can occur 
in an autocatalytic manner at the sequence-predicted site Gly-His-Lys199, as 
demonstrated by site-directed mutagenesis. However, alternative cleavage motifs were 
used whenever Lys199 was mutated to Ala. An activated neurobin molecule might 
excessively scan for cleavable motifs in a neurobin proenzyme molecule. This would 
particularly make sense assuming an activation mechanism in which intermolecular 
interactions only cease upon cleavage induced domain rearrangements. Supporting such a 
concept of scanning for alternative cleavage motifs is the recent finding, that thrombin 
can use alternative cleavage sites on a substrate when the primary cleavage position was 
mutated (Yu et al., 2007b).  
Whether neurobin can also be activated by other proteases is unknown yet. Also, whether 
the observed further processing within the protease domain is of physiological relevance 
or due to e.g. unphysiologically high concentrations of the refolded protease domain after 
purification or the mycHis-tagged neurobin in the ER of HEK293T cells, could not be 
addressed with our available tools. An inactivating effect of such intradomain processing 
was suggested by reduced binding of fragmented protease domain to a benzamidine 
column.  
Further analysis of autocatalytically activated wild-type neurobin under non-reducing 
conditions suggested that protease domain and the membrane-anchored N-terminal part 
were not covalently linked. This missing linkage might result from the absence of the 
predicted disulfide bridge, or alternatively, from a secondary not yet defined cleavage in 
front of the activation domain. Whether the protease domain remains at the plasma 
membrane or is released needs further investigations. In fact, shedding of TTSPs has been 
reported previously (Hansen et al., 2004; Kim et al., 2005). 
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4.5 Neurobin characteristics in the light of the x-ray 
structure of human DESC1 
 
Several peculiarities struck us while characterizing neurobin. For example, neurobin 
constructs with a C-terminally tagged protease domain did not allow production of 
secreted proteins in any of the tested expression systems. Besides, subcellular distribution 
of such constructs differed from that of the untagged counterparts.  
Another astonishing feature of neurobin was the potential lack of a disulfide bridge 
between the zymogen activation region and the protease domain although the suitable 
Cys residues are located in the expected sequence positions. 
Tags are known to cause altered protein folding and/or sorting and can even act as 
aggregation chaperones (Jain et al., 2000). The lack of the disulfide linkage might simply 
be explained by postulating that Cys187 and Cys188 in the zymogen activation region 
react with one another. However, folding/secretion and the missing linkage phenomena 
might both be explicable by analogy considering knowledge gathered from the recent 
analysis of the x-ray structure of human DESC1 (Kyrieleis et al., 2007). In the crystal 
structure of DESC1 Kyrieleis et al. detected a salt bridge between the carboxylate group 
of the C-terminal Ile244 and the guanidyl group of Arg135 (all chymotrypsin numbering), 
which can stabilize a hydrophobic patch on the surface of the protease opposite to the 
catalytic left. In neurobin, the corresponding Arg235 is conserved and Ile244 is Leu. All 
other amino acids generating the hydrophobic patch are also conserved except Tyr208 in 
DESC1, which is Phe in neurobin, therefor even increasing the hydrophobicity of the area. 
Of note, hepsin was crystallized with its N-terminally preceeding scavenger receptor 
cysteine rich (SRCR) domain rigidly bound to a similar hydrophobic patch on the surface 
of its protease domain (Somoza et al., 2003). As Kyrieleis et al. analyzed, these 
hydrophobic patches and a hydrophobic canyon that can accommodate the zymogen 
activation region are conserved in all four subfamilies of the TTSPs. Therefore, Kyrieleis 
et al. postulate a general mode of interaction of TTSPs with their preceding non-catalytic 
domain(s) via these hydrophobic patches (Figure  4.2). Arg120 in the middle of the 
hydrophobic patch of DESC1 is postulated to form a salt bridge with the SEA domain. 
This Arg120 is also conserved in neurobin. Thus, also the protease domain of neurobin 
might be fixed and oriented by rigid binding to the SEA domain making a covalent 
linkage dispensable. Given the above assumptions are correct, it is obvious that both 
folding/stabilization of the protease domain and its interactions with the SEA domain 
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would be hampered by the presence of the mycHis tag. Influences on sorting and 
activation characteristics would thus find a direct explanation. 
 
 
 
Figure  4.2: Solid-surface representations of human hepsin (A), human DESC1 (B), human 
matriptase (C) and human enteropeptidase (D). The enzymes are rotated around a vertical axis for 
180° in comparison with the standard orientation where the catalytic cleft points towards the reader. 
Hepsin (A) is shown bound to the SRCR domain, which is drawn as golden Cα-trace. Hydrophobic 
residues are in blue, and polar residues are in red. The corresponding residues Ile244 (DESC1), 
Val244 (matriptase) and Thr244 (hepsin) are shown in ball-and-stick models. Taken from (Kyrieleis 
et al., 2007). 
 
4.6 FGF-2 is cleaved by neurobin 
 
Neurobin processed 17-kDa FGF-2 to defined products of 13, 8.5, 6.4 and 4.3 kDa and 
N-terminal sequence analysis confirmed neurobin preference for Lys or Arg in the P1 
position. The available data do not yet allow us, however, to define a sequence specificity 
of neurobin. Further experiments are needed to elucidate whether neurobin displays 
tightly defined amino acid selectivity in the P2 - P4 positions and specificity may also be 
controlled by an induced-fit mechanism or exosite interactions between substrate, the 
protease domain and/or the SEA domain of neurobin.  
Proteolytic processing of FGF-2 was recently reported to occur by the hyaluronan-
binding protease from human plasma (Etscheid et al., 2004). Similar to our finding, 
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proteolytic processing was inhibited by heparin. Degradation of FGF-2 was first reported 
to occur during incubation with plasmin (Saksela et al., 1988). 
Interestingly, histochemical localization of FGF-2 in the cerebellum revealed strong 
expression in Purkinje cells with a distribution very similar to the distribution of neurobin 
(Matsuda et al., 1994; Reynolds et al., 2005), indicating that FGF-2 could indeed be an in 
vivo substrate of neurobin. Since FGF-2 plays a critical role in neuronal development 
(Abe and Saito, 2001; Ortega et al., 1998), cleavage of FGF-2 by neurobin may modulate 
FGF-2-dependent functions during cerebellar development. 
 
4.7 Considering the cleavage specificity of neurobin 
 
 
In our in vitro analysis only FGF-2 but not laminin, fibronectin or FGF-7 were processed 
by neurobin. Also in cell culture experiments neurobin displayed restricted proteolytic 
activity as discussed in the context of self-activation.  
 
We also investigated a FGF-2 variant directed to the conventional ER/Golgi-dependent 
secretion pathway by an N-terminally fused calsyntenin secretion signal. Though 
appearing straight forward, the approach bears other difficulties. It is known for example, 
that introducing FGF-2 to this secretory pathway does not grant efficient secretion and 
that the formation of intra- and intermolecular disulfide bonds alter the folding of the 
molecule (Chen et al., 2007). Indeed, though well expressed, we had difficulties to detect 
the FGF-2 variant in the medium and we could never observe neurobin mediated 
cleavage of FGF-2 accuulated in the secretory pathway. It is fair to assume that neurobin 
is capable of self-activation already in the ER, since wild-type neurobin always appeared 
to be quantitatively processed when analyzing extracts of transfected cells. Therefore, the 
inability of neurobin to cleave the FGF-2 variant introduced to the secretory pathway 
could be taken as a further hint for selective cleavage under physiological conditions. 
 
Similarly, in co-expression experiments with other proteins the proteolytic activity of 
neurobin was low or selective as observed for example in the case of the glutamate 
receptor delta 2 (GluRδ2) subunit. GluRδ2 was chosen for co-expression experiments 
because of its specific expression at parallel fiber-spine synapses in cerebellar Purkinje 
cells (Landsend et al., 1997). The mature form of the murine GluRδ2 protein consists of 
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984 amino acids of which 73 % are topologically exposed to the protease domain of 
neurobin. In three independent co-transfection experiments, co-expression with active 
neurobin but not with the S/A mutant leads to a moderately increased signal intensity of 
predominantly one band, running slightly higher than the 25 kDa marker band (Figure 
 4.3).  
 
Figure  4.3: Western blot analysis of HEK293T cell extracts co-transfected with a cDNA construct of 
the glutamate receptor delta 2 (GluRd2) fused to a C-terminal ONEstrep tag and either pcDNA-
vector (p), wild-type neurobin (w) or the S/A mutant thereof (s). Reproducibly, especially one bands 
detected running at about 27 kDa was stronger in the cotransfections of GluRd2 with wild-type 
neurobin. Molecular mass markers in kDa are indicated at the right. 
 
It would be exiting to investigate whether conditions exist, under which this neurobin-
dependent cleavage(s) of GluRδ2 can be enhanced. Particularly, since the GluRδ2 
subunit (which is not known to occur in functional ionotropic glutamate receptors) was 
reported to exert its function on cerebellar LTD and motor learning via protein 
interactions of its C-terminal cytosolic domain (Uemura et al., 2007; Yawata et al., 2006). 
Exactly this segment, following on the cytosolic side of the last of three transmembrane 
helices, would be released from the rest of the GluRδ2 protein upon cleavage by neurobin 
in the last extracellular loop. Besides, limited proteolysis of the GluR subunit 3 by γ-
secretase was recently proposed as mechanism to increase specializations among closely-
related GluR subunits (Meyer et al., 2003). It was beyond the scope of this thesis to go 
into detail of the potential physiological relevance of GluRδ2 processing by neurobin. 
However, the initial observation is again good evidence, that neurobin displays strong 
cleavage site selectivity although the primary binding pockets of the catalytic cleft accept 
a considerable variety of different amino acids.  
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Interesting in this context was also the observation that the chromogenic substrate with 
only Arg preceding the pNA group was not cleaved by neurobin, while trypsin control-
experiments suggested good substrate characteristics of the molecule. 
4.8 Considerations concerning the cleavage of FGF-2 by 
neurobin  
 
50 % of FGF-1 (acidic fibroblast growth factor, the closest relative of FGF-2 in the entire 
FGF-family) were reported to occur in an unfolded state at physiological temperature 
(Zakrzewska et al., 2004). If the same was true for FGF-2, one could argue that the 
observed cleavages by neurobin are rather unspecific since it is well known that unfolded 
proteins are more sensitive to proteolytic activity (Hubbard, 1998). An argument against 
this possibility of unspecific FGF-2 degradation is, however, that thrombin is able to 
process the high molecular weight (HMW) forms of FGF-2 in vitro and in endothelial 
cells, but not the short FGF-2 form we analyzed (Yu et al., 2007b) - and the protein 
substrate specificity of thrombin in vitro is not as high as might be assumed, as was 
learned e.g. from the multiple in vitro cleavages of the microtubule associated protein tau 
(Arai et al., 2005). 
In the light of such findings it would also be interesting to examine neurobin activity 
towards the HMW forms of FGF-2 to learn more about the potential physiological 
relevance of our results. Particularly, it might be interesting to see, whether heparin 
binding of the HMW forms of FGF-2 has the same protective effect as was observed for 
the 17 kDa form. It can not be excluded, that under physiological conditions neurobin 
cleavage modulates the activity of only certain FGF-2 isoforms. In the spinal cord for 
example, the HMW forms interact with an assembly and splicing factor of the splicing 
machinery, called survival of motor neuron protein (SMN) because its absence leads to 
fatal degeneration of motor neurons (Claus et al., 2003). Neurobin, initially detected in 
spinal cord, might participate in the modulation of SMN-induced effects by possibly 
cleaving the HMW forms of FGF-2 under physiological conditions. 
 
Possibly, the first cleavage of FGF-2 by neurobin occurs after Arg116. Since, from the in 
vitro digests neither by N-terminal sequencing from gels nor by MS measurement we got 
evidence for FGF-2 fragments spanning NTYR116-SRKY. This suggests that all other 
cleavages might occur after the postulated primary (or lead) cleavage, C-terminally of 
Arg116. FGF-2, lacking this C-terminal fragment might retain some of its signaling 
functions while not binding to proteoglycans any longer. Thus, neurobin would render an 
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alternative to the processing of proteoglycans by HtrA1 (Hou et al., 2007) to promote 
long range FGF-2 signaling. However, it is probably more likely that cleavages by 
neurobin – be it in a defined sequential or in a random order – might function as a local 
off switch for FGF-2 signaling, similar to e.g. neprilysin, a surface-bound metallo-
protease, which slows down angiogenesis by FGF-2 degradation (Goodman et al., 2006). 
 
We never observed FGF-2 cleavage by neurobin in our cell culture experiments. For the 
secretion of FGF-2, direct interactions with heparin sulfate proteoglycans are essential 
(Zehe et al., 2006) and we found FGF-2 attached to the surface of transfected COS7 cells 
– very likely via proteoglycans. Thus, neurobin might not encounter FGF-2 in an 
unbound state or bound in a way that is compatible with cleavage. And, since heparin 
suppresses FGF-2 cleavage by neurobin (see figure 3.18), cleavage might be prevented. 
Additionally, our finding might be due to the used cell lines and/or used cell culture 
conditions. 
 
Interestingly, x-ray structures of FGF-2 bound to heparin or bound to heparin plus the 
FGF receptor, respectively, reveal that the cleavage positions determined by our N-
terminal sequencing are rather surface exposed (Figure  4.4). It would be interesting to see 
whether heparin-binding still protects FGF-2 when bound to the receptor. Possibly, e.g. 
conformational changes upon receptor binding enable neurobin to cleave FGF-2 in a 
quasi two dimensional arrangement at the plasma membrane. In such a model, neurobin 
would exert its function to prevent self-stimulation of Purkinje cells secreting FGF-2 for 
e.g. signaling via FGF receptors 1 of type IIIb, which are specifically expressed on 
neighboring granule neurons in the cerebellum (Beer et al., 2000). 
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Figure  4.4: Ribbon models of FGF-2 x-ray structures in gray with the basic amino acids preceding 
the neurobin-cleaved bond highlighted in red. A, FGF-2 in complex with a heparin hexamer (brown) 
(PDB ID: 1BFC). B, FGF-2 (seen from the bottom side relative to A) in a ternary complex with FGF 
receptor 1 (green) and heparin (black) (PDB ID: 1FQ9). In both, A and B at least some of the 
cleavage motifs recognized by neurobin are exposed on the surface of the structures and should 
principally be accessible to the protease.  
 
Given these difficulties and uncertainties in experiments using COS7 or HEK293T cell-
lines, the analysis of FGF-2 cleavage by neurobin in cell-culture/in vivo should probably 
include neurobin-transfected rat Purkinje neuron cultures, either cotransfected with FGF-
2 cDNA or incubated with exogenously applied recombinant FGF-2. 
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5 Materials and Methods 
 
5.1 Chemicals and Additives  
 
Acetic acid (Fluka, puriss.p.a) 
Acetone (Fluka, puriss.p.a) 
AEBSF, 4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride; Pefabloc SC (Roche) 
Agarose (Eurogentech) 
Ampicilline (Appligene) 
Aprotinin (Roche Diagnostic) 
APS, ammonium peroxy sulphate (Fluka, puriss.p.a) 
Bacto agar (Difco) 
Bacto tryptone (Difco) 
Benzamidine (Fluka) 
Blocking Reagent, casein digest (Amersham) 
Bromphenol blue (Sigma) 
BSA, bovine serum albumin (Serva, Promega) 
Calcium chloride dihydrate (Fluka, puriss.p.a) 
DMSO, dimethylsulphoxide (Sigma)  
dNTPs, desoxyribonucleoside triphosphates (Promega) 
E64, Cys-protease inhibitor (Sigma) 
EDTA, ethylene diamino tetraacetic acid (Fluka, puriss.p.a) 
Ethanol (Fluka, puriss.p.a) 
Ethidium bromide (pharmacia) 
FCS, fetal calf serum (Biochrom AG, Berlin) 
Fluorescent Mounting Medium (DAKO) 
Glacial acetic acid (Fluka, puriss.p.a) 
Glutamine (Sigma) 
Glycerol 87 % (Fluka, puriss.p.a) 
Glycine (Fluka, purum) 
HAT, media suplement 50x (Sigma) 
HCl, hydrochloric acid (Fluka, puriss.p.a) 
Hepes, N-(2-hydroxyethyl)piperazine-N’-2-ethane sulfonic acid (Serva) 
Imidazole (Fluka) 
Isopropanol (Fluka, puriss.p.a) 
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Leupeptin (Roche) 
Magnesium chloride hexahydrate (Fluka, puriss.p.a) 
β-Mercaptoethanol (Fluka, puriss.p.a) 
MES (Sigma) 
Methanol (Fluka, puriss.p.a) 
MOPS (Sigma) 
Pepstatin, Asp-protease inhibitor (Sigma) 
PFA, paraformaldehyde (Fluka) 
Phosphoramidon, metalloprotease inhibitor (Sigma) 
PLL, poly-L-lysine (Sigma) 
PMSF, phenylmethanesulfonylfluoride, Ser-protease inhibitor (Fluka) 
Ponceau S (Sigma) 
Potassium acetate (Fluka) 
Potassium chloride (Fluka) 
SDS, sodium dodecyl sulfate (Fluka, puriss.p.a) 
Sodium chloride (Fluka, puriss.p.a) 
Sodium hydroxide (Fluka, puriss.p.a) 
StrepTactin (IBS) 
Sulfosalicylic acid 
TEMED, tetramethylethylendiamine (BioRad) 
Trichloracetic acid (Fluka, puriss.p.a) 
Trichlormetane (Fluka, puriss.p.a) 
Tris base (AppliChem) 
Triton X-100 (Fluka) 
Tween 20 (Serva) 
Yeast extract (Difco) 
 
5.2 Buffers, Media and Solutions 
 
Ampicilline stock: 100 mg/ml in UHP water, filtered (0.22 µm filter) 
Blocking Buffer: 1 ml 20x PBS, 2 ml FCS (use exp./old aliquots), 0.02 g 
glycine, adjust volume to 20 ml by adding UHP water 
Blocking solution:  5 % blocking reagent (Amersham) in TBS-T 
DNA Loading Buffer (5x): 0.2 % (w/v) bromophenole blue, 0.2 % (w/v) xylene cyanol 
FF, 25 % glycerol 
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DMEM+: Dulbecco’s modified Eagle’s medium without sodium 
pyruvate (GibcoBRL), 10 % FCS, additional 2 mM L-
glutamine, HAT 
EDTA (0.5 M): 37.22 g disodium EDTA·2H2O in 160 ml water, ad NaOH 
(4.4 g) till solution gets clear, add water to volume of 200 
ml 
Fixative (4 % PFA) 60 ml water (50°C), 4 g PFA (add 0.5 M NaOH till PFA is 
dissolved), 5 ml 20x PBS, 4 g sucrose, add water to final 
100 ml, check pH (should be 7.2 - 7.4).  
5x(reducing) Lämmli buffer: 250 mM Tris-Cl (pH 6.8), 10 % (w/v) SDS, 0.005 % (w/v) 
bromophenole blue, 50 % (v/v) glycerol, (500 mM 
dithiothreitol) 
LB Agar: LB Medium, 15 g/l bacto agar, autoclave, (add 100 µg/ml 
Amp.) 
LB Medium: 10 g/l bacto tryptone, 5 g/l yeast extract, 10 g/l NaCl, 
autoclave, (eventually add 50 µg/ml Amp.) 
lower Tris (SDS-PAGE gel): 1.5 M Tris·Cl, pH 8.8, 0.04 % SDS 
Lysis Buffer: 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 % Triton X-
100 (to 10 ml aliquots add one “Complete, EDTA-free; 
Protease Inhibitor Cocktail Tablet” from Roche) 
PBS-: 140 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM 
KH2PO4, pH 7.4 
PBS+: PBS- containing 0.9 mM CaCl2 and 0.5 mM MgCl2 
Ponceau S: 2 % Ponceau S, 30 % trichloracetic acid, 30 % sulfosalicylic 
acid, in UHP water 
SDS-PAGE running buffer: 25 mM Tris·Cl, pH 7.5, 190 mM glycine, 0.1 % SDS 
“Semi-dry” Blotting buffer: 39 mM glycine, 48 mM Tris (add solid, no pH adjustment 
required), 3.75 ml 10 % SDS, 200 ml methanol add water to 
1 L 
Solution A (Transfection): 500 mM CaCl2, sterile filtered (0.22 µm filter) 
Solution B (Transfection): 140 mM NaCl, 50 mM Hepes, 1.5 mM Na2HPO4, pH 7.05 
sterile filtered (0.22 µm filter) 
Stripping Buffer 200 mM Glycine, HCl, pH 2.2, 1%Tween-20, 0.1 % SDS 
TAE: 40 mM Tris·Cl, pH 8.0, 1 mM EDTA, 0.11 % glacial acetic 
acid 
TBS: 20 mM Tris·Cl, pH 7.5, 137 mM NaCl 
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TBS-T: 0.1 % Tween in TBS 
TE: 10 mM Tris·Cl, pH 7.5/8.0, 1 mM EDTA 
TFBI (transformation b. I): 30 mM KAc, 50 mM MnCl2, 100 mM KCl, 10 mM CaCl2, 
15 % glycerol (87 %, autoclaved), in sterile water 
TFBII (transformation b. II): 10 mM Na-MOPS (pH 7.0), 75 mM CaCl2 10 mM KCl, 15 
% glycerol (87 %, autoclaved), in sterile water 
Tris (1M): 121.1 g Tris base in UHP water, let cool down, adjust pH to 
7.4 (HCl), adjust volume to 1 L 
upper Tris (SDS-PAGE gel): 0.5 M Tris·Cl, pH 6.8, 0.04 % SDS 
 
 
5.3 Library construction 
To generate a protease domain enriched cDNA library, degenerated primers were 
designed. Therefore a Hidden Markov Model based alignment of murine trypsin-like 
serine proteases (http://supfam.org/SUPERFAMILY/index.html, version 1.61) was used 
to determine the most frequent sequences around the catalytic His57 and Ser195. Primers 
+degH: 5’-CCGGAATTC TKB RTI NTI WCI GCI GCN CAY TG-3’ and -degS: 5’-
CCGGAATTC GG ICC ICC ISW RTC NCC-3’ were generated that theoretically allow 
the amplification of more than eighty different protease sequences from the alignment. 
mRNA was isolated from spinal cord of three male and three female P 10 C57Bl/6 mice 
using RNeasy and Oligotex mRNA systems (both Qiagen). cDNA was synthesized from 
2 µg mRNA using PowerScript reverse transcriptase  (BD Biosciences) with 
oligo(dT)20 primers (Invitrogen) and 20 U RNasin. In the subsequent PCR reaction with 
degenerated primers 100 ng cDNA template and the Expand High Fidelity PCR System 
(Roche) with 1.75 mM Mg2+ were used. PCR was as follows: 3 min. 94°C, 5 cycles 25 
sec. 94°C, 40 sec. 45°C, 45 sec. 72°C, 30 cycles 15 sec. 94°C, 30 sec. 55°C, 45 sec. 
72°C, finally 5 min. 72°C. PCR products in the range of 400 to 600 bp were extracted 
from agarose gels and cloned into EcoRI-cut pBSSK+. DH5α E.coli strain (Invitrogen) 
was used for transformation. Transformants were plated on LB-agar plates with 100 
µg/ml ampicilin. More than 85 % of the clones in the resulting library contained protease 
sequences. 
5.4 Library screening 
The protease domain-enriched cDNA library was screened in an iterative two-step 
manner. First, 20 clones were randomly selected and submitted to DNA sequencing by a 
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CEQ 2000XL DNA Analysis System (Backman Coulter). Secondly, sequences occurring 
frequently in this selection were used to generate digoxigenin(DIG)-labeled DNA probes 
to deselect identical clones by colony hybridization following “The DIG System User’s 
Guide for Filter Hybridization” (Boehringer/Roche). The necessary components were 
from Roche. Totally six probes were generated by PCR using a dNTP mix in which 9 % 
of the dTTP was replaced by DIG-labeled dUTP. For the PCR the degenerated primers 
were used on plasmids containing the sequence encoding His57 to Ser 195 of the protease 
domains of tissue-type plasminogen activator, neurotrypsin, hepsin, neurosin, neuropsin, 
and additionally, a plasmid containing a non protease sequence (all plasmids were 
sequenced clones from the library). The probes could be used in combination and allowed 
the deselection of more than 90 % of the clones in the library. From the remaining library, 
clones were again selected randomly and analyzed by DNA sequencing. 
5.5 Full length cloning 
The BD SMART RACE cDNA amplification Kit was used. In the first strand cDNA 
synthesis for 5’ RACE the primer -atS: 5’-CCGGAATTCAACACGTCCCTTCAGGA-3’ 
was used. In addition to the supplied primers four gene specific primers were used in 
PCR amplifications (primers -GSP1: 5’-GACAGCTCGTGGTGCTTGTGGTTTA-3’ and 
-GSP2: 5’-CCACCTTCCCTTTGGCTTTGCTTACT-3’ for 5’ RACE; primers +GSP3: 
5’-GCTGTTGTGCGTCTGTCTTCGCCAG-3’ and +GSP4: 5’-CCCACCCAACTCAG-
ATGTAGT-3’ for 3’ RACE). The sequence information from 5’ and 3’ RACE was used 
to generate full length neurobin using primers +5’N: 5’-GGAGGATG-
ACTGTGCCACCCAGCA-3’ and -3’N: 5’-ATTTGCGGCCGCAGATATGCAAC-
CACTGAGCTTGA-3’ in a hot-start PCR reaction as follows: 1 min. 94°C, 42 cycles 15 
sec. 94°C, 30 sec. 68°C, 1.5 min (+ 2 sec./cycle) 72°C, 7 min. 72°C. To insert the 
catalytically inactivating S381A mutation the Transformer Site-Directed Mutagenesis Kit 
(BD Biosciences) was used. (Primer S>A: 5’-
CCAATGGTCCACCAGCATCACCCTGGCAGGC-3’).  
5.6 Eukaryotic expression constructs 
Full-length neurobin cDNA was cloned into pcDNA3.1 vector (Invitrogen) with either 
the endogenous stop codon to generate untagged neurobin (primers +5’N and –
NstopHindIII: 5’-CCCAAGCTTCTAGAGACCAGTTTTGGATGTGATCCA-3’) or in 
frame with the C-terminal myc-His tag from pcDNA3.1myc-His(-)A (primers +5’N and –
NHindIII: 5’-CCCAAGCTTGAGACCAGTTTTGGATGTGATCCA-3’). The construct 
bearing the S381A mutation and the myc-His tag was termed m1 and used as template in 
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megaprimer based site-directed mutagenesis for the generation of mutants m2 to m5, and 
the mutants K156A, K158A, K171A and K156AK158AK171A, respectively. 
5.7 RT-PCR analysis 
Liver, lung, spleen, kidney, heart cortex, cerebellum, and spinal cord were dissected from 
C57Bl/6 mice. The shock-frozen tissues were homogenized by either a rotor-stator or by 
shaking with stainless steel beads. Total RNA was prepared from 50 mg tissue. Of each 
RNA preparation, 1µg was used for cDNA synthesis using the ThermoScript RT-PCR 
System (Invitrogen) with oligo(dT)20 primers. 10% of the cDNA synthesis reaction was 
used for PCR with the Expand High Fidelity PCR System (Roche). The PCR cycles were 
as follows: for GAPDH 22 cycles 15 sec. 94°C, 30 sec. 58°C, 30 sec. 72°C, finally 5’ 
72°C. GAPDH-PCR (primers: +TGCCATCAACGACCCCTTC, -GGATGATGTTCTG-
GGCTGC) was restricted to 22 cycles to assess the exponential phase of product 
formation. No product was formed in the PCR even after 42 cycles, when the reverse 
transcriptase was omitted. For neurobin (primers +atH: 5’-CCGGAATTCTGTTTCAT-
ACGGGCTGCA-3’, -atS: 5’-CCGGAATTCAACACGT-CCCTTCAGGA-3’) 22 cycles 
15 sec. 94°C, 1 min. 60°C, 30 sec. 72°C, 20 cycles 15 sec. 94°C, 30 sec 60°C, 1 min. 
72°C, finally 7 min 72°C. The neurobin PCR product was cut with EcoRI, cloned into 
pBSSK+, and verified by sequencing. 
 
5.8 Verification of the 8 bp insertion in human neurobin 
using human genomic DNA 
During a blood donation, 8.5 ml of blood were collected in an extra BD Vacutainer with 
1.5 ml acid citrate dextrose. 0.2 ml of the leukocyte-enriched buffy coat preparation were 
collected (after 20 min at 4000 RCF) and submitted to genomic DNA preparation using a 
QIAamp DNA mini kit. The DNA was used as template in a standard PCR with primers 
+hNRBafterSer: 5’ –Ggtacagattctaaaggcat - 3’ and –hNRBafterStop: 5’ – Tgagctttaat-
ctacagaga - 3’ at 52°C annealing temperature. The resulting PCR product (running as 
expected for the calculated 175 bps) was purified using a QIAquick PCR purification kit 
and directly submitted to sequencing with primer +hNRBafterSer. 
 
5.9 Production, refolding and activation of recombinant 
neurobin 
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PCR using primers +NepPD: 5’-CCCGAGCTCGACGATGACGATAAAGTAGCAG-
GAGGCCAGGATGCT-3’ and –NHindIII resulted in a product encoding Val200-Leu431 
preceded by the enteropeptidase cleavage motive. Cloning into pET-28a(+) (Novagen) in 
frame with the N-terminal His-tag (via introduced SacI and HindIII sites) resulted in the 
protease domain expression construct (hisPD). After overexpression in the E.coli strain 
BL21 CodonPlus(DE3)-RIL (Novagen) hisPD was purified from washed and solubilized 
inclusion bodies using HisSelect nickel affinity resin (Sigma). Purified hisPD (600 
µg/ml) in 8 M urea, 0.1 M Tris-HCl pH 7.5, 4 mM DTT was slowly diluted into 10 
volumes of refolding buffer (0.1 M Tris-HCl pH 9, 0.5 M Arg, 150 mM NaCl, 3 mM 
GSH, 0.7 mM GSSG, 1.3 mM CaCl2) at 4°C using a peristaltic pump. The solution was 
stirred for at least 8 h and then dialyzed 3 times against 100 volumes of 20 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 1 mM CaCl2, 0.1 % Tween-20. The refolded HisPD was activated 
either directly or first concentrated using a Vivaspin 20 concentrator (MWCO 50 kDa, 
Vivascience AG). For activation 2 mg of HisPD were incubated overnight at room 
temperature with 1 U EKMax (bovine enteropeptidase, Invitrogen). For the cleavage 
assay with different chromogenic peptides, directly activated neurobin was used. For the 
subsequent experiments, neurobin (theor. pI 8.4), activated after concentration and 
additionally purified by cation-exchange chromatography, to remove enteropeptidase 
(theor. pI 5.2), was used. For cation-exchange chromatography a MonoS PC1.6/5 (0.1 ml 
CV) on an Ettan chromatography system (Amersham Pharmacia Biotech, 0.1ml/min 
during all steps) was used. After loading and washing for 20 CV in buffer A (20 mM Tris 
pH 7.0, 15 mM NaCl, 0.1 % Tween-20, pH 7.0), a linear gradient to 100 % buffer B (20 
mM Tris pH 7.0, 1 M NaCl, 0.1 % Tween-20, pH 7.0) was applied within 20 CV. 
Purified neurobin was stored in 50% glycerol at –20°C for several months without 
detectable loss of activity. The yield was 200 µg active protease domain from 1 L E. coli 
culture.  
For size exclusion chromatography a Superdex200 (23.6 ml CV) was used on an Ettan 
chromatography system (0.5 ml/min) with 200 µl purified PD in a buffer containing 50 
mM Phosphate, pH 6.5, 50 mM NaCl and 0.1 % Tween.  
For trial purifications of via a benzamidine column, 0.5ml of Benzamidin Sepharose 4FF 
resin were used in gravity flow chromatography. 120 µg purified neurobin PD in 0.5 ml 
equilibration buffer (500 mM NaCl, 20 mM Tris pH 7.5, 0.1 % Tween) were used. 
Washing was done with the equilibration buffer (10 -15 CV) and elution with 2 CV 50 
mM glycine, pH 2.9, 0.1 % Tween (direct neutralization with 0.2 volumes 1M Tris, pH 
7.5). 
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5.10 Antibodies 
 
5.10.1 The neurobin-SEA domain antibodies R142 and R143 
Generation and expression of the antigen 
First the eukaryotic expression construct FcNRBSEAdomMycHis was generated. 
Therefore primers +NRBntermFCtag: CCCAGCGCTgCCGCCTGTGGAAAAGACTCT 
and -NRBendeSEAmycHis: cccAAgcttgtgacctctatgaataattgtgcg were used in a standard 
PCR with full length neurobin template and 58°C annealing temperature. Via 
Eco47/HindIII, the resulting PCR product was ligated into a pcDNA3.1A(-)-based 
preconstruct (by G. Galliciotti) encoding the neuroserpin secretion signal and an Fc-tag 
followed by the sequence LeuGluValLeuPheGlnGlyPro which is specifically cleaved by 
PreScission protease (GE Healthcare) between the Gln and Gly residues (Cordingley et 
al., 1990). The resulting FcNRBSEAdomMycHis encodes the SEA domain containing 
only a C-terminal MycHis-tag upon PreScission-cleavage of its N-terminal Fc-tag 
(Similarly, five other constructs were generated encoding, after the Fc-tag, the whole 
extracellular part of neurobin - with and without C-terminal MycHis-tag and with and 
without the catalytic Ser195 mutated to Ala, and with only the protease domain, C-
terminally tagged with MycHis. All these latter constructs suffered from ill secretion 
and/or insufficient detectability (see results section). 
For the calcium phosphate transfection of HEK293T cells, growing in four 500 cm2-
plates (>90 % confluent), 2 mg FcNRBSEAdomMycHis were used in combination of 20 
ml of each transfection buffer A and B. 5 hours post transfection the plates were washed 
3 times with 100 ml PBS and 100 ml serum free DMEM were added. Three days post 
transfection, the medium was collected, centrifuged for 20 min at 200 RCF, shock-frozen 
in liquid nitrogen and stored at – 20°C. Of a small aliquot, efficient secretion of the Fc-
tagged SEAmycHis protein was checked by Western Blotting using a tetra His antibody. 
Purification of the antigen and rabbit immunization 
After thawing, 30 mg of sodium azide were added to 300 ml of the medium tested for Fc-
tagged SEAmycHis protein expression. The samples were filtered using folded paper 
filters (Schleicher and Schuell) and loaded onto 1.2 ml of Protein A Sepharose 4FF resin 
(econo-system, 0.25 ml/min, overnight). Then washing at 0.5 ml/min with 50 ml wash 
buffer (500 mM NaCl, 50 mM Tris pH7.5, 0.1% Tween 20) followed by 30 ml Cleavage 
Buffer (50 mM Tris pH 7.0, 300 mM NaCl, 1 mM DTT, 0.1 % Tween) was applied. Then 
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the resin was incubated in 2 ml Cleavage buffer containing 70 µl PreScission for 16 h at 
4° C with 3x resin resuspension. The released SEAmycHis protein was eluted in 6 ml 
Cleavage buffer and loaded onto 0.3 ml His Select (Sigma) resin at 0.07 ml/min (econo 
system, Bio-Rad Laboratories, UK). 12 ml washing buffer (50 mM Tris pH 7.5, 300 mM 
NaCl, 20 mM imidazol, 0.1 % Tween) at 0.2 ml/min preceded the elution (50 mM Tris 
pH 7.5, 300 mM NaCl, 250 mM imidazol, 0.1 % Tween) at 0.1 ml/min. All purification 
steps were carried out at 4°C. 
Two rabbits (strain Hsdllf:NZW) were immunized each with 30 µg of eukaryotically 
expressed and purified SEAmycHis protein. Two 30 µg boost injections followed two 
and five months later.  
Antibody purification using prokaryotically expressed SEA domain 
First For this, a standard PCR with primers +NRBseaNheI: CCCgctagcGCCGC-
CTGTGGAAAAGACT and –NRBendeSEAstop: ccAAgcttCTActtgtgacctctatgaata on a 
full length neurobin template was performed with 52°C annealing temperature. Cloning 
into pET-28a(+) (Novagen) in frame with the N-terminal His-tag (via introduced NheI 
and HindIII sites) resulted in the full-length SEA domain expression construct with N-
terminal His-tag (HisfullSEA). The construct was used to transform E.coli strain 
BL21CodonPlus(DE3)-RIL. A 1 L culture of such a clone expressing HisfullSEA was 
grown at 37°C with 180rpm till OD600 reached 1. Then, 0.8 mM IPTG were added for 
induction. After 3h (37°C, 180rpm) cells were pelleted (20min. 10‘000 RCF). The pellet 
was resuspended in 100 ml 50 mM Tris, pH 7.5, 500 mM NaCl, DNaseI and stored at -
20°C. For purification via HisSelect resin, the bacteria suspension was thawed and lysed 
by passing twice through the Emulsiflex. The supernatant containing the fraction of 
cytosolic HisfullSEA was cleared (20 min 10‘000xg) and loaded overnight onto 1.9 ml 
HisSelect resin (4°C). 70 ml wash buffer (50mM phosphate buffer, pH 8, 0.5 M NaCl, 
0.1% Tween-20, 10mM imidazol) were used at 0.4 ml/min and elution (50mM phosphate 
buffer, pH 8, 0.5 M NaCl, 0.1% Tween-20, 250mM imidazol) was performed at 
0.2ml/min. Total 50 mg of purified HisfullSEA were obtained out of 1L E.coli culture. 12 
mg of HisfullSEA were directly coupled to 0.5 ml NHS-activated Sepharose 4FF 
(Amersham Biosciences) resin. This HisfullSEA column in an econo-system was used to 
affinity-purify IgG fractions obtained from 10 ml rabbit sera aliquots using Protein A 
Sepharose 4FF chromatography (Amersham Biosciences). As in all cases mentioned 
below, affinity purification was done by overnight loading of a sterile filtered IgG-
containing fraction diluted in sterile-filtered PBS (final volume 100 ml). After extensive 
washing in PBS containing 0.1 % Tween-20, elution was achieved with 50 mM Glycin 
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pH 2.8-2.9 containing 0.1 % Tween-20. 0.8 ml elution fractions were collected in 
eppendorf tubes containing 0.2 ml 1M Tris, pH 7.5 and gently shaken for rapid complete 
neutralization. All steps were carried out at 4°C. 
The affinity-purified antibody preparations from both rabbits R142 and R143 gave 
virtually identical results both in western blotting and indirect immunofluorescence. 
 
5.10.2 The neurobin-PD antibodies R156 and R158 
Two rabbits (strain Hsdllf:NZW) were immunized each with 50 µg of prokaryotically 
expressed, purified and refolded HisPD  protein (see above and results section). Two 30 
µg boost injections followed two and four months later. However, the resulting antibodies 
mainly reacted with the His-tag-containing N-terminal fragment (not part of neurobin, see 
results section). 
5.10.3 Peptide antibodies 
N-Term of neurobin as antigen 
A peptide containing the first 22 aa of neurobin (MARGQPRRSEEQWTALQNRTEC) 
was synthesized couplet to keyhole limpet haemocyanin (KLH) and used to immunize 
and boost two rabbits (R134 + R135) at Primm Biotech in Italy. 4 mg of the peptide were 
coupled to 0.4 ml NHS-activated Sepharose 4Fast Flow (Amersham Biosciences) and 
used to affinity-purify IgGs from an IgG fraction of 10 ml serum submitted to ammonium 
sulfate (AS) precipitation (43 % final AS-concentration w/v, by dropwise addition of 20 
ml 65 % AS, overnight, 4°C, dialysis in Spectral Por 3 membrane 3x3 L PBS, 20 h, 4°C) 
or directly from 10 ml serum aliquots. 
Protease domain loop of neurobin as antigen  
Similar to the approach at Primm we tried to raise peptide antibodies against a loop of the 
neurobin protease domain by immunizing two rabbits (R1+R2) and two guinea pigs 
(GP1+GP2) at Pineda Antibody Services in Berlin. For the choice of the peptide 
(neurobin residues 258-271 + Cys for coupling to KLH) we relayed on a report by Parker 
(Parker et al., 1986) and on our own considerations. First, we checked for surface 
exposure to maximize the chance of epitope accessibility in histochemistry. For this 
purpose the neurobin protease domain was aligned to the superposition of several x-ray 
determined serine protease domains, as shown in Figure  4.1. Secondly, to reduce the risk 
of crossreactivity, peptide sequences with maximal differences were selected from 
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sequence alignments of neurobin with the HAT/DESC family members of different 
species. The peptides were subsequently checked for minimal nearly exact matches by 
blasting against the translated sequence databases. Finally, to increase the chance of good 
antigenicity the peptide displaying at least some differences to the corresponding rat 
neurobin peptide was chosen since the rabbit and guinea pig genomes are not available 
yet. Additionally the peptide had been checked for charged and bulky hydrophobic amino 
acids which in general are thought to increase antigenicity.  
The fifth boost of rabbit serum R1 looked most promising in IF. Therefore 10 ml of fifth 
boost serum were affinity-purified on a column prepared by coupling 10 mg peptide 
neurobin258-271+Cys to 0.5 ml NHS activated Sepharose 4FF. With 9.3 mg purified 
IgGs (8.8% of the average amount of IgGs in 10 ml serum) the yield was very high and of 
good purity as determined by silver staining.  
 
5.11 Peptide cleavage assays 
Chromogenic peptide substrates were from Sigma, Fluka, Chromogenix and Jerini, 
respectively. Trypsin was from hog pancreas (Fluka). Absorptions at 405 nm were 
measured from 100 µl reaction volumes in 96 well plates using a 1420 Multilable 
Counter VICTOR3 (PerkinElmer). The initial assay buffer was 20 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1 mM CaCl2, 0.1 % Tween-20. Calcium was omitted subsequent assays, 
unless otherwise stated. For testing of different peptides, reaction volumes contained 4.5 
µl activation buffer with refolded neurobin (HisPD) activated with enteropeptidase 
(EKMax), or 150 nM trypsin. In control reactions no enzyme, HisPD, or EKMax were 
used, respectively. In the later assays 250 µM GHRpNA were incubated with 30 nM 
activated MonoS-purified neurobin protease domain. All reactions were monitored by 5 
minute-interval absorbance measurements. Trypsin control reactions rapidly reached 
completion, whereas reactions containing activated neurobin did not reach completion 
within the 2 hrs measurement period. 
 
5.12 Protein cleavage 
Proteins at a concentration of 100 ng/µl in either PBS (FGF-7, 140 amino acid form from 
AMGEN, gift from Dr. Sabine Werner), TBS (bovine fibronectin from Sigma) TBS-T 
(laminin from Invitrogen), or 10 mM Tris-HCl, pH 7.6 (human FGF-2 from Invitrogen) 
were added to the enzyme in 50 mM Tris-HCl, pH 7.5 with 150 mM NaCl. The resulting 
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concentrations were 50 ng/µl protein substrate and 0.5 ng/µl enzyme. After 4 h at 37°C 
the reaction was stopped by the addition of loading buffer.  
5.13 FGF-2 cleavage analysis 
For Edman degradation, FGF-2 incubated with neurobin was separated on a 4–12% 
NuPAGE gel (Invitrogen) using MES-buffer and transferred onto a PVDF membrane. 
Bands were cut out and sequenced on a Procise 492 cLC Sequencer (Applied Biosystems, 
CA, USA) at the Functional Genomics Center Zurich. Additionally, FGF-2 incubated 
with neurobin was directly submitted to matrix assisted laser desorption time of flight 
mass spectrometry (MALDI-TOF-MS) analysis. The analysis was performed on a 
Ultraflex II (Bruker, Germany) at the Functional Genomics Center Zurich.  
 
5.14 Cloning of eukaryotic expression constructs of FGF-2 
and GluRδ2 
The cDNA of FGF-2 was retrieved from P10 mouse spinal cord cDNA using primers 
+F1: 5’- cccGctagcATGGCTGCCAGCGGCATCA – 3’ and -F2: 5’- cccGcggccgcGCT-
CTTAGCAGACATTGGAAG – 3’ in a PCR with 45 cycles and 57°C annealing 
temperature. Cloning into pcDNA3.1 ONEstrep (special preconstruct from D. Lüscher) 
via the introduced NheI and NotI sites, allows FGF-2 expression with three repeated 
strep-tag motifs at the C-terminus. 
The construct was used as template in a standard PCR with primers +F3: 5’- 
cccGTTAACgctgccagcggcatcacct – 3’ and -F4: 5’ – cccGcggccgctcaGCTCTTAGCA-
GACATTGGA – 3’. Cloning of the PCR product into pEAK8CstSecr (preconstruct from 
S. Hettwer) via the introduced HpaI and NotI sites allowed expression of an untagged 
FGF-2 variant directed to the conventional secretory pathway via the N-terminal 
secretion signal of human calsyntenin-1.  
PCR with the primer pair +F1 and –F4 and cloning into pcDNA3.1 ONEstrep via the 
NheI and NotI sites, allows expression of normal low molecular weight FGF-2.  
The cDNA of GluRδ2 in vector pBKSApa37-14 (gift from Masayoshi Mishina) was used 
in a PCR with primers +G1: 5’ – cccGctagcATGGAAGTTTTCCCCTTGCT – 3’ and -
G2: 5’ – cccGcggccgcTATGGACGTGCCTCGGTC – 3’. Cloning into pcDNA3.1 
ONEstrep via the introduced NheI and NotI sites, allows GluRδ2 expression with three 
repeated strep-tag motifs at the C-terminus. 
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5.15 Cell culture and transfection 
HEK293T cells (human embryonic kidney cell line) were grown in 3 cm plates with 2 ml 
Dulbecco’s modified Eagle’s medium without sodium pyruvate (Invitrogen), 10% FCS 
and 2 mM L-glutamine at 37 °C in 10 % CO2. For calcium-phosphate transfection, 2 µg 
DNA were used. In cotransfection experiments up to 5 µg of each plasmid were used. 
COS 7 cells were transfected with LipofectamineTM2000 (Invitrogen) like suggested in 
the manual. The growth-media were exchanged 5 hrs after transfection. Cells were 
further processed 24 or 48 h post transfection. 
5.16 SDS-PAGE, Western Blotting and Silver Staining 
12.5 or 15 % polyacrylamide gels were used. With purified protein, concentration was 
determined by UV absorption measurement at 280 nm using the calculated extinction 
coefficient. Protein concentration in extracts was determined with the BCA system 
(Pierce). Whole cell extracts were prepared by lysing the cells in lysis buffer. For 
deglycosylation extracts (30 µg protein) were treated with 2.5 mU endoglycosidaseH 
(Roche) or 0.5 U N-glycosidaseF (Roche) and 50 mM Na-acetat pH 5 for 1h at 37°C. 
Before loading, samples were boiled for 5 minutes in reducing Lämmli buffer. 25 µg 
protein extract were loaded per lane. Proteins were transferred to nitrocellulose 
(Schleicher and Schuell) or PVDF membranes (Millipore). Transfer quality was 
controlled with Ponceau S staining. The membranes were blocked in TBS-T containing 
10 % Western Blocking Reagent (Roche diagnostics GmbH, Mannheim) over night at 4 
°C. The membranes were incubated for 2 h at RT with TBS-T containing 1 µg/ml of 
affinity-purified polyclonal anti SEA domain antibody or 0.1 µg/ml anti Tetra His 
monoclonal antibody (Qiagen). Membranes were washed 3 times for 5 min in TBS-T. 
Membranes were incubated for 45 minutes in TBS-T containing either 25 ng/ml 
peroxidase-coupled goat anti rabbit IgG (Chemicon) or 0.2 µg/ml peroxidase-coupled 
goat anti mouse IgG (KPL). Membranes were washed again 3 times for 10 min. in TBS-
T. After incubation in CHEMIGLOWTM substrate (Alpha Innotech Corp), 
chemiluminescence was detected by a CCD Camera (Alpha Innotech Corp). For silver 
staining, SDS-PAGE gels were fixed with 30% EtOH and 10% acetic acid for 30 min 
(room temperature) to ON (4°C). Reducing and crosslinking was achieved with 30% 
EtOH, 6.8 g NaOAc, 0.2 g Na2S2O3, 0.25 ml glutaraldehyde (50%) in 100 ml final 
volume for 10 min. This was followed by washing of the gels 4 times 3 min with H2O, 
silver incubation with 0.2 g AgNO3 and 20 ml formaldehyde in 100 ml final volume for 
15 min; washing for 1 min with H2O and development with 5 g Na2CO3 and 20 ml 
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formaldehyde in 200 ml final volume. Development was stopped with 3% acetic acid for 
5-10 minutes. The gels were rinse with H2O and dried by heating in a low pressure 
atmosphere.  
 
5.17 Immunofluorescence 
COS-7 cells grown on glass cover slips were fixed one day post transfection in 4 % 
paraformaldehyde (PFA) in PBS for 10 min. Then the cells were incubated for 1 h in 
blocking buffer (PBS, 10 % FCS, 3 % BSA, 0.5 % glycine) and incubated overnight at 4 
°C in blocking buffer containing 3 µg/ml affinity purified anti SEA IgG or 2 µg/ml Tetra 
His monoclonal antibody (Qiagen). Cells were rinsed and washed 3 times for 10 min in 
TBS-T and then incubated for 45 minutes at room temperature in blocking buffer 
containing 1.3 µg/ml Cy3-labeled donkey anti rabbit IgG (Jackson) or 2.5 µg/ml FITC- 
labeled donkey anti mouse IgG (Jackson). Washing was performed as before. In case of 
the analysis of permeabilized cells 0.1 % saponin was included in all antibody incubation 
steps.  The cover slips were mounted upside down onto glass slides using 
DarkoCytomation Mounting Medium (DarkoCytomation) and stored at 4 °C. Analysis 
was performed on a Leica Leitz DM RXE microscope with PL Fluotar objectives. 
Pictures were taken with a Leica DFC350FX camera.  
5.18 Histochemistry 
Anesthetized P10 mice were perfused with PBS containing 4% PFA and the isolated 
organs incubated in an increasing sucrose gradient. Cryosections of tissue tek (Sakura) 
embedded brain (20 µm) sections on glass slides were processed with a similar protocol 
as cells in immunofluorescence (omission of the Tetra His and corresponding secondary 
antibody, inclusion of 0.1 % saponin during antibody incubation). Analysis was 
performed on a Olympus IX81F-2 microscope. Pictures were taken with an F-ViewII 
camera. 
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